

# SAHPRA

South African  
Health Products  
Regulatory Authority



## 2021/22 ANNUAL PERFORMANCE PLAN

JANUARY 2021

## **SOUTH AFRICAN HEALTH PRODUCTS REGULATORY AUTHORITY (SAHPRA'S) GENERAL INFORMATION**

**Physical Address:** Building A  
Loftus Park  
402 Kirkness Street  
Arcadia  
PRETORIA

**Postal Address:** Private Bag x828  
Pretoria  
0001

**Telephone number:** +2712 501 0300  
**E-mail Address:** [enquiries@sahpra.org.za](mailto:enquiries@sahpra.org.za)  
**Website Address:** [www.sahpra.org.za](http://www.sahpra.org.za)


**ISBN:** 978-0-621-49074-9

**RP:** 04/2020

## TABLE OF CONTENTS

EXECUTIVE AUTHORITY STATEMENT .....	III
CHAIRPERSON OF THE BOARD STATEMENT.....	IV
ACCOUNTING OFFICER STATEMENT .....	VI
OFFICIAL SIGN-OFF.....	IX
LIST OF ABBREVIATIONS/ ACRONYMS .....	X
GLOSSARY OF KEY TERMS AND DEFINITIONS.....	XI
<b>PART A: OUR MANDATE .....</b>	<b>1</b>
1. UPDATES TO THE RELEVANT LEGISLATIVE AND POLICY MANDATES .....	1
1.1 Constitutional Mandate.....	1
1.2 Relevant Legislative Mandate .....	1
1.3 Policy Mandate .....	7
2. UPDATES TO INSTITUTIONAL POLICIES AND STRATEGIES .....	7
3. UPDATES TO RELEVANT COURT RULINGS .....	11
<b>PART B: OUR STRATEGIC FOCUS.....</b>	<b>13</b>
1. UPDATED SITUATIONAL ANALYSIS .....	13
1.1 External Environment Analysis .....	13
1.2 Internal Environment Analysis .....	16
<b>PART C: MEASURING OUR PERFORMANCE .....</b>	<b>21</b>
1. INSTITUTIONAL PROGRAMME PERFORMANCE INFORMATION .....	21
1.1 Programme 1: Leadership and Support.....	21
1.2 Programme 2: Health Products Authorisation.....	27
1.3 Programme 3: Inspectorate and Regulatory Compliance .....	33
1.4 Programme 4: Clinical and Pharmaceutical Evaluation.....	37
1.5 Programme 5: Medical Devices and Radiation Control.....	43
2. UPDATED KEY RISKS AND MITIGATION FROM THE STRATEGIC PLAN.....	49
3. PUBLIC ENTITIES.....	51
4. INFRASTRUCTURE PROJECTS .....	51
5. PUBLIC-PRIVATE PARTNERSHIPS.....	51
<b>PART D: TECHNICAL INDICATOR DESCRIPTIONS.....</b>	<b>52</b>
<b>ANNEXURES .....</b>	<b>78</b>
ANNEXURE A: MATERIALITY AND SIGNIFICANCE FRAMEWORK .....	78

## EXECUTIVE AUTHORITY STATEMENT



The South African Health Products Regulatory Authority's (SAHPRA) Annual Performance Plan 2021/22, which is based on the 2020/21 - 2024/25 Strategic Plan serves as a guide for the entity to deliver on its core mandate as prescribed in the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), as amended.

In addition, the Annual Performance Plan comprehensively responds to the priorities identified by Cabinet of 6<sup>th</sup> administration of democratic South Africa, which are embodied in the Medium-Term Strategic Framework (MTSF) for period 2019 - 2024. SAHPRA is structured to support delivery on the National Development Plan (NDP): Vision 2030; the Sustainable Development Goals (SDGs) which builds on the work started under the Millennium Development Goals; the National Health Insurance which lays the foundation for moving South Africa towards universal access to quality health care services in accordance with section 27 of the Constitution. The Annual Performance Plan is also aligned to the Presidential Health Compact (2019), towards achieving social justice; through enabling access to affordable good quality, safe and efficacious medicines and medical devices.

SAHPRA was recently established as a schedule 3A public entity, however the Board places high on its agenda SAHPRA's proper alignment to achieve the requisite social and economic impact, which is the primary reason for its existence. The Ministry of Health therefore commits itself to providing the necessary support to accelerate performance towards the achievement of the ultimate goals of MTSF, NDP, SDGs and the Presidential Health Compact; as SAHPRA claims its rightful place as one of the leading regulators in the continent and globally.

I wish the Board and management well as they work shoulder to shoulder in pursuit of the fulfillment of these national aspirations.

A handwritten signature in black ink, appearing to read 'Z. Mkhize', with a stylized flourish at the end.

**DR ZWELINI MKHIZE, MP**  
**EXECUTIVE AUTHORITY**  
**MINISTER OF HEALTH**



## CHAIRPERSON OF THE BOARD STATEMENT



A compact and well-articulated legislative and policy environment is arguably a pivotal pillar and instrument for any regulator to give effect to the critical role that SAHPRA is mandated to fulfill. Nowhere was that more evident than during the first full financial year of operating as SAHPRA, emerging out of the erstwhile Medicines Control Council.

SAHPRA operates in a complex legislative environment that straddles multiple areas and players. This amplifies a need for robust stakeholder engagement. Assuming an extended mandate that incorporates medical devices and radiation control in addition to an older mandate necessitated a close scrutiny of development in the policy environment. Some of these developments have significant socio-economic implications; most notably, being in the area of cannabis pursuant to the new dynamics following the Constitutional Court Judgement in September 2018. This has spurred enormous commercial

debates and interests and has placed some urgent regulatory considerations on the doorstep of SAHPRA. The Board has encouraged SAHPRA's direct engagement in the public discourse on these matters at all possible levels of the organisation so as to work collaboratively with relevant stakeholders to shape policy.

Another notable development is the advent of the Presidential Health Summit Compact which also has policy implications for SAHPRA. Collectively, these developments require policies that are both industry-wide and localised to SAHPRA's own internal operations; including a series of frameworks that require developments. The Compact recognises the need for capacitation of SAHPRA and other similar entities in the healthcare domain which includes a review of funding processes.

Appreciating the massive capacity gaps SAHPRA currently has as it continues to evolve, I am pleased with, and have confidence in, the leadership and support the Board has afforded to SAHPRA management through its committees; thereby ensuring that SAHPRA is able to assume leadership in its respective areas.

Our focus is on shaping a bright future for SAHPRA based on a solid organisation with a clear direction; supported by a conducive legislative framework, internal processes and systems and human capital to build sustainable organisational capacity.

I also have pleasure in joining our Honourable Minister and the Chief Executive Officer in presenting the Annual Performance Plan.

A handwritten signature in dark ink, appearing to read 'H. Rees', is positioned above a horizontal line.

**PROFESSOR HELEN REES**

**CHAIRPERSON OF THE BOARD**

**SOUTH AFRICAN HEALTH PRODUCTS REGULATORY AUTHORITY**

## ACCOUNTING OFFICER STATEMENT



The year 2020 was characterised by unparalleled levels of change and uncertainty as the world grappled with the pandemic caused by the Coronavirus disease (COVID-19), an infectious disease caused by a newly discovered coronavirus, SARS- CoV-2. The rapid spread of this virus resulted in the COVID-19 pandemic that led to a dramatic loss of human life worldwide and presented an unprecedented challenge to public health, food systems and the world of work. The economic and social disruption caused by the pandemic has been devastating.

The advent of COVID-19 saw an increasing dependence on SAHPRA for its science-based regulatory decisions and leadership in ensuring that all health products including those for the treatment of COVID-19 are safe, efficacious and of high quality so that the health and well-being of South Africans are protected. As SAHPRA joined the country and the world at large to embrace 4IR in response to the pandemic, the need for digitised workflows and smart digital tools became an essential requirement. SAHPRA had to fast track the digitisation of some of its processes to enable remote working as well as introduce an online submission portal and smart digital tools to enable uninterrupted interactions with the stakeholders. This prevented cumbersome paper submissions and moved to more environmentally friendly and efficient online processes. Being stringent, yet agile in its approaches remains to be a key response approach by the regulator as South Africa continues to be plagued by this disease.

While SAHPRA responds to the COVID-19 pandemic, it cannot lose focus on supporting key national priorities such as the implementation of National Health Insurance (NHI) Scheme aimed at ensuring universal health care access. Furthermore, critical projects such as the clearance of the backlog remain to be a priority for the Authority. An additional priority for the regulator that was made acute during the country's response to COVID-19 is post market surveillance and pharmacovigilance. As regulators across the globe apply reliance mechanisms and joint regional assessment programs, it is anticipated that this will enable them to invest the required resources to strengthen the national post market surveillance and pharmacovigilance programs.

To ensure health products that are safe, efficacious and of high quality, SAHPRA is responsible for the monitoring, detection, assessment, understanding and prevention of adverse effects. An important

aspect of pharmacovigilance are the systems and processes that holders of certificates of registration employ to ensure that safety related data is collected, analysed, reported with mitigations and Corrective and Prevention Actions, where required. SAHPRA aims to strengthen its capacity and capabilities to inspect the pharmacovigilance systems of holders of certificates of registration against established SAHPRA and global guidelines. Proactive post-market surveillance is necessary to prevent the risk of having sub-standard or falsified health products in the country thus compromising the safety of the people of South Africa. SAHPRA's relationship with the Centre for Quality Assurance Medicines laboratory is being formalised and this will assist SAHPRA in sampling products from the market for testing and ensure that licensed entities are complaint and unlicensed entities are brought to book.

The amendment to the Medical Device Regulations is currently in progress. The proposed amendments take into consideration mandatory requirements for the quality management systems of manufacturers and distributors, thereby paving the way for a more robust regulatory process. SAHPRA will focus on the medical devices and in vitro diagnostics unit to ensure that these long-awaited regulations are implemented post consultation with the relevant stakeholder. The operational framework for Radiation Control, which is the implementation unit within SAHPRA of the Hazardous Substances Act and regulations related to Group III and Group IV hazardous substances need to be reviewed and aligned with international standards and best practices. The current gaps in the regulation of these products in partnership with the National Nuclear Regulator need urgent attention to ensure the safety of the public.

The Health Summit Compact recognised that capacity was a stumbling block for SAHPRA's ability to deliver fully on its mandate. To this effect, SAHPRA has embarked on a phased capacitation plan to ensure that it is a well-capacitated and a high-performance organisation that executes its mandate by achieving the desired national health outcomes. Filling of critical vacant positions, while retaining highly skilled individuals in its core business will be priority for the 2021/22 financial year. Being able to generate the required revenue for the many programs that SAHPRA needs to implement to ensure that it is an efficient regulator remains to be a priority. The new fees were gazetted on 22 December 2020 and are being implemented. It will however be important that the marked increase in fees will be accompanied by improved effectiveness of SAHPRA.

SAHPRA recognises that it needs to be locally relevant and work with various national stakeholders to contribute to addressing the socio-economic challenges of the country. To this effect, SAHPRA has initiated mechanisms wherein it is reviewing its processes to determine if it is enabling to the local sector as it contributes to the national agenda while it positions itself internationally.



SAHPRA needs to align itself with other international health product regulators in order to ensure it achieves world-class standards while being relevant to the local context. SAHPRA's affiliation to the Pharmaceutical Inspection Co-operation Scheme (PIC/S) in 2007 was a noteworthy achievement, enabling SAHPRA to become a globally recognised Inspectorate. SAHPRA will be undergoing re-assessment by PIC/s in 2021 to maintain its current membership. It is anticipated that in 2021 SAHPRA will achieve a WHO Maturity level 3, while it works towards a WHO Maturity level 4 in the year 2025.

Its journey from a fledgling entity to a professional, efficient and effective regulator will require considerable effort from SAHPRA management and the Board in ensuring the organisation is adequately resourced to achieve its strategic objectives. For SAHPRA to be relevant and to achieve world-class standards, it is obligatory for this evolving entity to address the needs of its stakeholders, especially the South African public.

As SAHPRA works towards deepening its scientific review base and to also build globally aligned review methodologies and practices, it will focus on the following priorities:

- Applying global standards of Good Review Practices;
- Applying reliance on a risk-based approach;
- Working towards being a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; and
- Becoming a World Health Organisation Listed Authority.

SAHPRA is on the right trajectory of being an agile, conscientious and socio-economically transformative globally positioned African health products regulator with a sustainable positive impact on long and healthy lives of South Africans.

I am immensely pleased to present our Annual Performance Plan.



**DR BOITUMELO SEMETE-MAKOKOTLELA**  
**CHIEF EXECUTIVE OFFICER**  
**SOUTH AFRICAN HEALTH PRODUCTS REGULATORY AUTHORITY**

## OFFICIAL SIGN-OFF

It is hereby certified that this Annual Performance Plan:

- was developed by the management of SAHPRA under the guidance of the Board;
- takes into account all the relevant policies, legislation and other mandates for which SAHPRA is responsible; and
- accurately reflects the impact and outcomes which the SAHPRA will endeavour to achieve during the 2021/22 financial year.



ADV TEBOHO PETER NTHOTSO  
COMPANY SECRETARY



MR DEON POOVAN  
SENIOR MANAGER:  
INSPECTORATE AND REGULATORY COMPLIANCE




MR TOHLANG SEHLOHO  
SENIOR MANAGER: CLINICAL EVALUATION MANAGEMENT



MS PORTIA NKAMBULE  
CHIEF REGULATORY OFFICER



MS CHRISTELNA REYNECKE  
CHIEF OPERATIONS OFFICER  
HEAD OF PLANNING



PROF HELEN REES  
CHAIRPERSON OF THE BOARD



MR KUDA KAPFUMVUTI  
SENIOR MANAGER:  
HEALTH PRODUCTS AUTHORISATION



MS SILVERANI PADAYACHEE  
SENIOR MANAGER:  
PHARMACEUTICAL EVALUATION MANAGEMENT

VACANT


SENIOR MANAGER: MEDICAL DEVICES AND  
RADIATION CONTROL



MS SIMPHIWE MATSABE  
ACTING CHIEF FINANCIAL OFFICER



DR BOITUMELO SEMETE-MAKOKOTLELA  
CHIEF EXECUTIVE OFFICER  
ACCOUNTING OFFICER



DR ZWELINI MKHIZE, MP  
MINISTER OF HEALTH

APPROVED BY:

## LIST OF ABBREVIATIONS/ ACRONYMS

<b>API</b>	Active Pharmaceutical Ingredient
<b>B-BBEE</b>	Broad-Based Black Economic Empowerment
<b>COVID-19</b>	Coronavirus disease
<b>GCP</b>	Good Clinical Practice
<b>GDP</b>	Good Distribution Practice
<b>GLP</b>	Good Laboratory Practice
<b>GMP</b>	Good Manufacturing Practice
<b>GWP</b>	Good Warehouse Practice
<b>GVP</b>	Good Vigilance Practice
<b>HFC</b>	Healthcare Finance Committee
<b>ICH</b>	International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
<b>ICT</b>	Information and Communication Technology
<b>IT</b>	Information Technology
<b>IVD</b>	<i>In Vitro</i> Diagnostic
<b>MTSF</b>	Medium Term Strategic Framework
<b>NCE</b>	New Chemical Entity
<b>NDP</b>	National Development Plan
<b>NDoH</b>	National Department of Health
<b>NHA</b>	National Health Act
<b>NHI</b>	National Health Insurance
<b>NNR</b>	National Nuclear Regulator
<b>NRA</b>	National Regulatory Authority
<b>PIC/S</b>	Pharmaceutical Inspection Co-operation Scheme
<b>QMS</b>	Quality Management System
<b>SAHPRA</b>	South African Health Products Regulatory Authority
<b>SAPC</b>	South African Pharmacy Council
<b>SDGs</b>	Sustainable Development Goals
<b>WHO</b>	World Health Organization

## GLOSSARY OF KEY TERMS AND DEFINITIONS

<b>Complementary Medicines</b>	<p>The term “complementary medicines” means any substance or mixture of substances that-</p> <p>(a) originates from plants, fungi, algae, seaweeds, lichens, minerals, animals or other substance as determined by the Authority;</p> <p>(b) is used or purporting to be suitable for use or manufactured or sold for use-</p> <p>(i) in maintaining, complementing or assisting the physical or mental state; or</p> <p>(ii) to diagnose, treat, mitigate, modify, alleviate or prevent disease or illness or the symptoms or signs thereof or abnormal physical or mental state of a human benign or animal; and</p> <p>(c) is used-</p> <p>(i) as a health supplement</p>
<b>Health Product</b>	<p>The term ‘health product’ as is contained within the ambit of this document only, means medicines, medical devices, radioactive nuclides, listed electronic products (medical), complementary medicines, veterinary medicines, biological and biosimilars</p>
<b>Ionising Radiation</b>	<p>This means radiation consisting of high energy radiation i.e. X-rays or gamma rays and/or sub-atomic particles, with sufficient energy to cause ionization in the medium through which it passes</p>
<b>In vitro diagnostic</b>	<p>In vitro diagnostic (IVD) means a medical device, whether used alone or in combination, intended by the manufacturer for the in vitro examination of specimens derived from the human body solely or principally to provide information for diagnostic, monitoring or compatibility purposes</p>
<b>Medical Devices</b>	<p>A “medical device” means any instrument, apparatus, implement, machine, appliance, implant, reagent for in vitro use, software, material or other similar or related article, including Group III and IV Hazardous Substances contemplated in the Hazardous Substances Act, 1973 (Act No. 15 of 1973) -</p> <p>(a) intended by the manufacturer to be used, alone or in combination, for humans or animals, for one or more of the following:</p> <p>(i) diagnosis, prevention, monitoring, treatment or alleviation of disease;</p> <p>(ii) diagnosis, monitoring, treatment, alleviation of or compensation for an injury;</p> <p>(iii) investigation, replacement, modification or support of the anatomy or of a physiological process;</p> <p>(iv) supporting or sustaining life;</p> <p>(v) control of conception;</p> <p>(vi) disinfection of medical devices; or</p> <p>(vii) providing information for medical or diagnostic purposes by means of in vitro examination of specimens derived from the human body; and</p> <p>(b) which does not achieve its primary intended action by pharmacological, immunological or metabolic means, in or on the human or animal body, but which may be assisted in its intended function by such means</p>
<b>Medicine</b>	<p>The term “medicine” –</p> <p>(a) means any substance or mixture of substances used or purporting to be suitable for use or manufactured or sold for use in -</p> <p>(i) the diagnosis, treatment, mitigation, modification or prevention of disease, abnormal physical or mental state or the symptoms thereof in humans; or</p>

	<p>(ii) restoring, correcting or modifying any somatic or psychic or organic function in humans; and</p> <p>(b) includes any veterinary medicine</p>
<b>Non-Ionising Radiation</b>	This means radiation that does not carry enough energy to break molecular bonds and ionize atoms
<b>Radiation</b>	This means the emission of electromagnetic energy moving through space. It includes radiowaves, microwaves, infrared light, ultraviolet, X-rays, gamma rays and sub-atomic particles. High-energy radiation causes ionization in the medium through which it passes



## PART A: OUR MANDATE

### 1. UPDATES TO THE RELEVANT LEGISLATIVE AND POLICY MANDATES

#### 1.1 Constitutional Mandate

The Constitution of the Republic of South Africa, 1996, places an obligation on the state to progressively realise socio-economic rights, including access to healthcare.

Section 27 of Chapter 2 of the Bill of Rights of the Constitution states the following with regards to healthcare, food, water and social security:

- Everyone has the right to have access to healthcare services, including reproductive healthcare; sufficient food and water; and social security, including appropriate social assistance if they are unable to support themselves and their dependents.
- The state must take reasonable legislative and other measures within its available resources to achieve the progressive realisation of each of these rights, and no one may be refused emergency medical treatment.

#### 1.2 Relevant Legislative Mandate

The South African Health Products Authority's objective is to provide for the monitoring, evaluation, regulation, investigation, inspection, registration and control of medicines, scheduled substances, clinical trials and medical devices, in vitro diagnostics and related matters in the public interest.

Since its establishment in February 2018, as a schedule 3A entity of the National Department of Health (NDoH), there has been no updates to its legislative and policy mandates. The cornerstone legislative mandates of SAHPRA are derived from the national Constitution, the National Health Act, 2003 (Act No. 61 of 2003) and the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), as amended (herein after referred to as "the Medicines Act").

Pursuant to the expansion of SAHPRA's mandate, to incorporate inter alia, the regulation and control of radiation-emitting devices and radioactive materials the following are various pieces of legislation that define the legislative framework within which SAHPRA executes its mandate:

### **1.2.1 The National Health Act, 2003 (Act No. 61 of 2003)**

It provides a framework for a structured uniform health system within the Republic, taking into account the obligations imposed by the Constitution and other laws on national, provincial and local government with regard to health services. The objectives of the National Health Act (NHA) are to:

- Unite the various elements of the national health system into a common goal to actively promote and improve the national health system in South Africa;
- Provide for a system of co-operative governance and management of health services, within national guidelines, norms and standards, in which each province, municipality and health district must address questions of health policy and delivery of quality health care services;
- Establish a health system based on decentralised management, principles of equity, efficiency, sound governance, internationally recognised standards of research and a spirit of enquiry and advocacy which encourage participation;
- Promote a spirit of co-operation and shared responsibility among public and private health professionals and providers and other relevant sectors within the context of national, provincial and district health plans;
- Create the foundations of the health care system, and
- Must be understood alongside other laws and policies that relate to health.

### **1.2.2 The Medicines and Related Substances Act, 1965 (Act No. 101 of 1965) as Amended**

Amended by Amendment Act, 2008 (Act No. 72 of 2008) and Amendment Act, 2015 (Act No. 14 of 2015) and enacted in May 2017, the Act enabled, among others, the establishment of SAHPRA, the licensing of manufacturers and importers of Active Pharmaceutical Ingredients (APIs), and the regulation of medical devices.

In terms of the Medicines Act, the objects of the Authority are to provide for the monitoring, evaluation, regulation, investigation, inspection, registration and control of medicines, scheduled substances, medical devices, radiation control, clinical trials and related matters in the public interest.

The Act also provides for registration and control of veterinary medicines in such a way as to ensure that they are produced, distributed and used without compromising human and animal health. Antimicrobials intended for use in animals and registered under the Medicines Act can only be administered or prescribed by a veterinarian.

As per section 2b (1) of the Medicines Act, the Authority must, in order to achieve its objects, ensure:

- The efficient, effective and ethical evaluation or assessment and regulation of medicines, medical devices, radiation emitting devices and radioactive nuclides that meet the defined standards of quality, safety, efficacy and performance, where applicable;
- That the process of evaluating or assessing and registering of medicines, medical devices, radiation emitting devices and radioactive nuclides is transparent, fair, objective and concluded timeously;
- The periodic re-evaluation or re-assessment and ongoing monitoring of medicines, medical devices, radiation emitting devices and radionuclides;
- That evidence of existing and new adverse events and reactions, interactions, and signals emerging from post-marketing surveillance and vigilance activities are investigated, monitored, analysed and acted upon;
- That compliance with existing legislation is promoted and achieved through a process of active inspection and investigation; and
- That clinical trial or clinical performance study protocols are assessed according to prescribed scientific, ethical and professional criteria and defined standards.

In executing its functions, the Authority may:

- Liaise with any other regulatory authority or institution and may, without limiting the generality of this power, require the necessary information from, exchange information with and receive information from any such authority or institution in respect of:-
  - matters of common interest; or
  - a specific investigation; and
  - Enter into agreements to co-operate with any regulatory authority in order to achieve the objects of the Medicines Act.

### **1.2.3 Hazardous Substances Act (Act No. 15 of 1973)**

The Hazardous Substances Act provides for the efficient, effective and ethical evaluation and licensing of radionuclides (Group IV hazardous substances) and listed electronic products (Group III hazardous substances – including but not limited to electronic generators of ionizing or non-ionizing radiation).

SAHPRA is only responsible for the regulation of Group III and Group IV hazardous substances.

Section 3 of the Hazardous Substances Act refers to regulation of Group III hazardous substances, i.e. listed electronic products, and section 3A refers to regulation of Group IV hazardous substances, i.e.

radionuclides.

#### **1.2.4 Other Related Legislations**

Due to the complex environment that SAHPRA operates in, the following is a series of related legislation impacting on, and influencing the functioning of SAHPRA:

- **Fertilisers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947):**

Provides for the registration of fertilisers, farm feeds, agricultural remedies, stock remedies, sterilising plants and pest control operators. To regulate or prohibit the importation, sale, acquisition, disposal or use of fertilisers, farm feeds, agricultural remedies, and stock remedies. Furthermore, it governs the use of antimicrobials for growth promotion and prophylaxis/metaphylaxis, and the purchase of antimicrobials over-the-counter (OTC) by the lay public (chiefly farmers).

- **Animal Diseases Act, (Act No. 35 of 1984):**

Provides for the control of animal diseases and parasites, for measures to promote animal health and for matters connected therewith.

- **Veterinary and Para-veterinary Professions Act, 1982 (Act No. 19 of 1982):**

Provides for the establishment, powers and functions of the South African Veterinary Council, for the registration of persons practising veterinary professions and para-veterinary professions, for control over the practising of veterinary professions and para-veterinary profession and for matters connected there with. It further makes provision for the compounding and or dispensing of any medicine which is prescribed by the veterinarian for use in the treatment of an animal which is under his or her professional care.

- **Drugs and Drug Trafficking Act, 1992 (Act No. 140 of 1992):**

Provides for the prohibition of the use or possession of, or the dealing in, drugs and of certain acts relating to the manufacture or supply of certain substances or the acquisition or conversion of the proceeds of certain crimes; for the obligation to report certain information to the police; for the exercise of the powers of entry, search, seizure and detention in specified

circumstances; for the recovery of the proceeds of drug trafficking; and for matters connected therewith.

In relation to cannabis, on 18 September 2018 the Constitutional Court declared: sections 4(b) and 5(b) (use and possession) read with Part III of Schedule 2 of the Drugs and Drug Trafficking Act, 1992 (the Drugs Act); and Section 22A(9)(a)(i) of the Medicines and Related Substances Act, 1965, read with Schedule 7 of Government Notice No. R. 509 of 2003, unconstitutional on the premises that they amount to an impermissible limitation of the right to privacy. The Court suspended the order of invalidity for 24 months (from 18 September 2018 to September 2020).

Following consultation with stakeholders, amendments to the Schedules of the Medicines Act aligned with the Constitutional Court judgement were published in Government Notice No. 586, Government Gazette No. 43347, issued on 22 May 2020. The Department of Justice and Constitutional Development responsible for the Drugs Act amendments, is still in the process of addressing the addressing the Concourt judgement.

- **Foodstuffs, Cosmetics and Disinfectants Act, 1972 (Act No. 54 of 1972) (as amended):**

Provides for the regulation of foodstuffs, cosmetics and disinfectants, in particular, quality standards that must be complied with by manufacturers, as well as the importation and exportation of these items.

- **Environmental Management Act: Waste Management Act, 1998 (Act No. 107 of 1998):**

Provide for co-operative, environmental governance by establishing principles for decision-making on matters affecting the environment, institutions that will promote co-operative governance and procedures for coordinating environmental functions exercised by organs of state; and to provide for matters connected therewith.

- **Health Professions Act, 1974 (Act No. 56 of 1974):**

Provides for the control over the education, training and registration for practising of health professions registered under the Act, and to provide for matters incidental thereto.



- **Nursing Act, 1978 (Act No. 50 of 1978):**

To consolidate and amend the laws relating to the professions of registered or enrolled nurses, nursing auxiliaries and midwives, and to provide for matters incidental thereto.

- **Pharmacy Act, 1974 (Act No. 53 of 1974):**

The South African Pharmacy Council (SAPC) in terms of Section 35A of the Pharmacy Act, 53 of 1974 regulates the practice of pharmacy within South Africa. SAPC ensures that all responsible pharmacists, pharmacy support personnel and pharmacy owners provide pharmaceutical services that complies with good pharmacy practice standards prescribed in both the Pharmacy Act and the relevant provisions of the Medicines and Related Substances Act. The Medicines Act, in Section 16(d), provides for possession of medicines or scheduled substance for sale by the pharmacists or a person licensed to own a pharmacy in terms of the Pharmacy Act, 1974 or a person who is the holder of a license as completed in section 22C of the Medicines Act. The SAPC has, in terms of Section 38A of the Pharmacy Act, appointed inspection officers to inspect pharmacies for monitoring compliance. The provisions of the Pharmacy Act include investigation of complaints received alleging misconduct or unprofessional conduct.

- **Customs and Excise Act, 1964 (Act No. 91 of 1964):**

Provides for the prohibition and control of the importation, export or manufacture of certain goods, and for matters incidental thereto.

A favourable legislative environment is fundamental to the operations of a regulator such as SAHPRA in supporting an effective execution of its mandate. There have been a few notable developments in SAHPRA's operating environment that have necessitated a review of its legislative and policy framework.

In the first instance, SAHPRA's role exists amid an extremely complex legislative context where there is a series of other players involved where SAHPRA has only a limited yet important regulatory role. A case in point is a role SAHPRA should be fulfilling through its representation at key ports of entry where there are goods that come into the country that fall within its legislative obligations, for their inspection, as per the Customs and Excise Act, cited above.

One of the key new responsibilities emanating from SAHPRA's extended mandate relates to radiation control, which has crucial elements falling within the jurisdiction of the Department

of Mineral Resources and Energy. Another responsibility concerns cannabis regulation, which cross-pollinates multiple ministries such as the Department of Justice and Correctional Services and the Department of Agriculture and Rural Development, to effect the country's focus on enhancing access to this medicinal product. As SAHPRA continues to mature into its role, it is becoming increasingly evident that there is a critical need to harmonise roles and responsibilities so as to avert the risk of an internal leadership vacuum or duplication of efforts and subsequent potential "conflict".

### 1.3 Policy Mandate

The court ruling on the recreational use of cannabis has spurred a considerable public interest and debate in relation to implications for medicinal applications of cannabis. In addition, there is commercial interest that is tied to a significant potential economic gain from the legalisation and subsequent industrialisation of cannabis. This is evidenced by small-scale growers who seek to play in that space, a vast majority of whom have been growing the cannabis herb illegally for many years. It is imperative that as an agile regulator, SAHPRA takes proactive action in tackling the regulatory framework relating to this area and strengthen collaborative partnerships with various government departments in bringing alignment to the various legislations supporting enhanced and broader access to cannabis-based products. The entity therefore anticipates that it will participate in the national policy discussions that pertain to legislative and policy framework considerations related to cannabis and the industrialisation thereof.

A second critical national policy discussion that SAHPRA is engaged in pertains to localisation of the pharmaceuticals sector. These deliberations, led by the National Economic Development and Labour Council (NEDLAC), will culminate into a national policy framework that would guide SAHPRA in executing its mandate in support of a national policy position.

## 2. UPDATES TO INSTITUTIONAL POLICIES AND STRATEGIES

In fulfilling its mandate, SAHPRA has taken the following key policies and strategies into consideration and has ensured that its worked in aligned to these:

- **United Nations Sustainable Development Goals**

The 2030 Agenda for Sustainable Development provides a blueprint for peace and prosperity for people and the planet. It contains 17 Sustainable Development Goals (SDGs) that need to be achieved through the partnership of all countries. More relevant to SAHPRA is SDG Goal 3, which aims to ensure health lives and promote well-being for all at all stages". The goal is further broken down to

target is further broken down to target 3.8 that focuses to “achieve universal health coverage including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all” and target 3b that focuses on supporting the “research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and in particular, provide access to medicines for all”.

- **The National Development Plan, Vision 2030**

The National Development Plan (NDP) is the blueprint for the South African government that aims to eliminate poverty and reduce inequality by 2030. Chapter 10 of the NDP focuses on providing quality health care for all. The implementation of the NDP is translated into the Medium-Term Strategic Framework (MTSF) 2019 – 2024. Priority 3: “Education, Skills and Health” of the MTSF is the responsibility of the NDoH. Although SAHPRA does not have a task directly allocated to it in the MTSF, it will support NDoH in achieving certain targets such as the outcome: “Universal health coverage for all South Africans achieved through the National Health Insurance” by being an enabler of accelerated product registration and regulation.

- **The National Drug Policy**

To ensure alignment of the MTSF to the National Drug Policy; which was adopted in 1995 with extensive support from the World Health Organisation (WHO). The Policy was adopted to serve the health care needs of South Africa in the following ways:

1. It offers a clear description of the approach by which pharmaceutical services in the country will be managed.
2. It offers guidance to stakeholders, including health care providers, suppliers of goods and services, and governmental and non-governmental agencies of ways in which they can contribute to achieving the policy's main aim.
3. It follows a clear and logical system for reducing inefficiency and waste and improving efficiency and effectiveness through the development of an adequate pharmaceutical infrastructure.
4. It facilitates the design, production and implementation of appropriate programmes for human resource development in health care.

- **The Nine-Pillar Presidential Health Summit Compact, 2018**

The primary goal of the Health Summit Compact is to strengthen and improve universal access to health and healthcare in South Africa. The following 9 pillars are commitments to strengthening the health system:

1. Augment Human Resources for health;
2. Ensure improved access to essential medicines, vaccines and medical products through better management of supply chains, equipment and machinery;
3. Execute the infrastructure plan to ensure adequate, appropriately distributed and well-maintained health facilities;
4. Engage the private sector in improving the access, coverage and quality of health services;
5. Improve the quality, safety and quantity of health services provided with a focus on primary health care;
6. Improve the efficiency of public sector financial management systems and processes;
7. Strengthen the governance and leadership to improve oversight, accountability and health system performance at all levels;
8. Engage and empower the community to ensure adequate and appropriate community-based care; and
9. Develop an information system that will guide the health system policies, strategies and investments.

Pillar 2 focuses on ensuring improved access to essential medicines, vaccines and medical products through better management of supply chain equipment and machinery. Within Pillar 2, SAHPRA is responsible for leading the intervention on regulation and registration through the support of the NDoH and private sector by ensuring that “through a collaborative process re-engineer regulatory processes to reduce delays in the registration of products and value innovation, thereby providing reasonable access to safe, effective and affordable products. SAHPRA has developed strategies to address the areas identified as follows:

*Clearing the current backlog*

SAHPRA has prioritised medicine applications based on the public health need and expedited the processes that take into account reliance approaches for medicines of public health benefit as a matter of critical concern. The regulatory processes have been re-engineered to reduce unnecessary bureaucracy and delays by re-engineering the operational models and revising business processes. Collaborative structures to introduce new medicines into pilot programmes to address high burden

diseases, particularly the human immunodeficiency virus, tuberculosis, cancer and other diseases of priority and adopted the novel regulatory mechanism of reliance and molecule-based registration.

#### *Reduction in the average time frame for the registration of product*

The approach taken by SAHPRA to accelerate the licensing of products in the backlog required a fundamental re-engineering of its processes, and this new methodology was also introduced into SAHPRA's 'Business as Usual' work. Key components of this effort included the harmonisation of SAHPRA's regulatory requirements and guidelines to reflect global best practice and the introduction of 'reliance' review pathways which allow sharing of product evaluation information between regulatory authorities, resulting in streamlining of decisions, reduced duplication of effort and acceleration of licensure processes.

#### *Implement reliance model*

In terms of Section 2b of the Act, SAHPRA may liaise with other authorities or institutions to exchange and receive information in a matter of common interest or a specific investigation, and may enter into agreements to cooperate with any regulatory authority in order to achieve the objects of the Act.

SAHPRA has adopted the following reliance policies:

- Full review – conduct complete scientific review for safety, quality, efficacy, Good Manufacturing Practice
- Abridge review – assess specific, pre-agreed areas of critical importance to SAHPRA's mandate to ensure safety the South African public
- Verified review – validate that application conforms to reference authorisation and provides required information.

#### • **Global Alignment**

As SAHPRA is positioning itself to ensure that it aligns with global regulatory frameworks and approaches, it is crucial that it undertakes the Global Benchmarking Assessment which is used by the World Health Organization to evaluate the regulatory systems of regulatory authorities. The benchmarking tool enables WHO to, amongst others, identify areas of strength and improvement as well as develop institutional development plans.



SAHPRA also plans to actively participate in the global regulatory environment to achieve global standards and its vision of being a globally relevant and competitive regulator. The engagement and active participation with international and regional regulators are key in reaching global standards as a regulator and its ability to work alongside other regulators in delivering its mandate.

- **Public Awareness**

SAHPRA will make a concerted effort to partner with relevant stakeholders to educate the public through implementing a public awareness programme. The programme will include providing access to the latest information on cutting edge advances in the health sector, new SAHPRA regulatory approaches for various health products as well as aspects pertaining to health products safety. Furthermore, SAHPRA aims to position its website as a trusted source of information. Other communication tools will also be used to engage with the public.

### 3. UPDATES TO RELEVANT COURT RULINGS

NO.	CASE	SUMMARY
1.	Minister of Justice and Constitutional Development and Others v Prince; National Director of Public Prosecutions and Others v Rubin; National Director of Public Prosecutions and Others v Acton and Others [2018] ZACC 30	<p>On 18 September 2018, the Constitutional Court found sections of the Medicines Act which restrict cannabis use to be unconstitutional in certain limited circumstances</p> <p>It is therefore not a criminal offence for an adult person to:</p> <ul style="list-style-type: none"> <li>• Use or be in possession of cannabis for his or her personal consumption in private; and</li> <li>• To cultivate cannabis in a private place for his or her personal consumption in private</li> </ul> <p>The Court did not make a distinction between using, possessing or cultivating cannabis for recreational or medicinal use</p> <p>SAHPRA was required, within 24 months from 18 September 2018, to amend the Medicines Act to comply with this judgement. In response to this, the Minister of Health, through SAHPRA, amended the Schedules to the Medicines and Related Substances Act, Act 101 of 1965 and published these in the Government Notice No. 586, Government Gazette No. 43347, on 22 May 2020. These amendments included removal of Cannabis as a plant from Schedule 7 of the Medicines and Related Substances Act, 101 of 1965. Instead, the psycho-active ingredient tetrahydrocannabinol (THC) is listed in Schedule 6, with specific exemptions made for industrial application of low-THC cannabis which contains 0,2 % percent or less of THC as a raw plant material or processed products manufactured from such material, intended for industrial purposes and not for human or animal ingestion</p>

NO.	CASE	SUMMARY
2.	Alliance Natural Health Products of South Africa v THE Minister of Health & Another [Case No:11203/2018]	<p>On 1 October 2020, the Pretoria High the Court reviewed and set aside the General Regulations promulgated on 25 August 2017 under General Notice 859 in GG 41064, to the extent that they apply to complementary medicines and health supplements that are not medicines or scheduled substances as defined in section 1 of the Medicines Act. The declaration of invalidity is however suspended for a period of twelve months to allow the SAHPRA to correct the defect</p> <p>On 29 October 2020, the Minister and SAHPRA filed an application for leave to appeal to have this judgment overturned. Since the Minister and SAHPRA are appealing the judgement, the General Regulations are therefore still in force</p>

## PART B: OUR STRATEGIC FOCUS

### 1. UPDATED SITUATIONAL ANALYSIS

The environment in which SAHPRA performs its regulatory role is largely shaped by the developments that emanate from its immediate internal and external milieu. These developments include significant internal structural, cultural, governance and organisational changes that are a natural consequence of the journey to transition into a Schedule 3A Public Entity. The changing political landscape, as well as socio-economic factors have placed a greater emphasis on health systems reform. The way that these developments will influence the organisation's overall regulatory performance in the short to medium term is of great significance to SAHPRA. It is also important to reflect on public health, government policy and industry trends that may have a considerable influence on our current and future regulatory role.

#### 1.1 External Environment Analysis

##### 1.1.1 PESTEL Analysis

A PESTEL analysis is a framework to analyse the key factors (Political, Economic, Sociological, Technological, Environmental and Legal) influencing an organisation from the outside.

##### *PESTEL analysis*

POLITICAL	
1.	The introduction of the 6th Administration following the recent elections has ushered in a renewed focus on reform and shift in policy. Public health reform is exemplified in the area prioritisation of Universal health coverage and the promulgation of the National Health Insurance Bill
2.	There is a plethora of legislations that affect the areas of SAHPRA's operations which straddle various departments that need to be co-ordinated through intergovernmental relations processes. This would include regulation of radiation emitting devices, management of opioid abuse as well as deregulation of cannabis
3.	Increasingly competitive government tenders, with punitive conditions attached for non-compliance, have been introduced
4.	The industry is still to transform and there is currently no sector chapter to promote self-regulation for sector transformation in line with government policies, mainly the B-BBEE Act
ECONOMIC (FINANCIAL)	
1.	There has been a change in the balance of power across the healthcare value chain as governments and medical aid providers start to exert more pressure on pharmaceutical companies to drop their prices
2.	The SA medical device market is estimated at R30 billion in 2019 and presents an opportunity to garner greater revenue and stimulate the local manufacturing industry. Compared with the pharmaceutical market, where domestic manufacturers are now able to meet 50% of demand in volume terms, South Africa's domestic medical device industry is small, with imports catering for 90% of the market by value
3.	The local pharmaceutical market is growing at just over 9% in value and this growth is ascribed to the increased demand for generics

4.	Nearly every therapeutic class currently has at least one generic equivalent available and sales of over-the-counter generics now also outstrip brand name products by almost R1 billion in value and more than 53 million units
5.	Global shortages of active pharmaceutical ingredients, which are key ingredients in the manufacturing process impact licensing and access within the South African market
6.	Weak economic growth means that the public health sector will be required to do more with fewer resources than initially planned. In essence, a weaker fiscus translates into South Africa needing to drive the transition to a greater fees contribution to its revenue as opposed to the fiscal contribution to its revenue
7.	There is a need for generic medicines in South Africa as more doctors and consumers opt for affordable, yet effective alternatives to expensive brand name medication
8.	In response to the COVID-19 outbreak, government introduced a massive social relief and economic support package of R500 billion, and part of this budget was allocated to health to respond to the coronavirus
9.	Non-private medical costs increased and labour productivity declines are the main direct costs related to the COVID-19 outbreak
10.	South Africa has been approached by vaccine manufacturers to consider bilateral purchasing agreements. The risk is that price negotiations are confidential, up-front payments may be lost should the vaccine not prove safe and efficacious
<b>SOCIAL/SOCIO-ECONOMIC</b>	
1.	The increasing rates of inequity and poverty amongst the different population groups in South African society is a clear indication of an increase in the number of vulnerable individuals that need a social safety network against sub-optimal and falsified health products that flood across porous borders into vulnerable third world markets
2.	In South Africa, generics are fast becoming the pillar of healthcare because of their affordability to public health and the fact that they make medicine accessible to the most vulnerable in society
3.	There seems to be social scepticism surrounding the success prospects of the NHI Scheme due to challenges that have been witnessed in state-owned enterprises
4.	There is a danger of misinterpretation of the Constitutional Judgement on the recreational use of cannabis. This could affect the medicinal use aspects that SAHPRA is responsible for which may necessitate urgent public education interventions and collaboration with other government departments such as Social Development, Trade and Industry, and Finance
5.	South Africa has participated in the COVID-19 vaccines global access (COVAX) Facility which was created to establish a pooled procurement mechanism to secure adequate and equitable supplies of vaccines at competitive prices for countries throughout the world, irrespective of their wealth status
6.	The NDoH will work with the SAHPRA to ensure that whichever vaccine being recommended or made available through the COVAX Facility has met all the regulatory requires of safety, efficacy, and quality
<b>TECHNOLOGICAL</b>	
1.	Digitisation of SAHPRA operations is imperative to optimise SAHPRA into a globally recognised space
2.	Technical advances and increasing trends in cyber-crimes create risks to unauthorised access to sensitive information. Data security is a growing business consideration that must prioritised
3.	Online purchasing sites are not adequately regulated and have a negative impact in that they enable ease of access to illegal importation of drugs that could make it hard for SAHPRA to detect
4.	Due to the COVID-19 outbreak, staff have been working remotely and therefore heavily relying on information technology. This has resulted in increased data costs for SAHPRA, within the limited budget in which it operates
<b>ENVIRONMENTAL</b>	
1.	An increase in reported cases of abandoned or recklessly handled radiation-emitting materials that are causing illnesses for neighbouring communities requires the urgent attention of SAHPRA's radiation control division
2.	SAHPRA must align to the global trends of greener industrial systems and should seek to align legislation and practice of licencing and inspections with stimulating industrial compliance
3.	The lockdown due to the COVID-19 pandemic has placed restrictions in terms of movement therefore resulting in a positive impact on the environment such as the improvement air quality and less waste and noise pollution
4.	The negative impact of the COVID-19 pandemic has been the increase of medical waste, haphazard use and disposal of personal protective equipment that creates environmental burden

LEGAL	
1.	There is a plethora of legislation that requires harmonisation in order to provide clarity for SAHPRA to discharge its role with greater efficiency and confidence, given the critical importance of legislation for SAHPRA's regulatory function
2.	The Constitutional Court judgment on cannabis requires urgent interventions in terms of proper policy frameworks
3.	The evolving universe of health product regulation necessitates focused efforts from SAHPRA to review the legal framework to ensure the regulatory compliance unit is properly aligned to enforce regulation at a global level
4.	A key area of law enforcement is that of false and misleading advertising that adversely impacts public safety

### 1.1.2 SWOT Analysis

#### SWOT Analysis

STRENGTHS	SWOT Analysis		WEAKNESSES
	STRENGTHS	WEAKNESSES	
	<ol style="list-style-type: none"> <li>1. Agility and autonomy of a Schedule 3A entity permits quicker responsiveness to the health products regulatory environment</li> <li>2. Re-engineered business process towards the novel reliance mechanisms places SAHPRA as a leader to develop rigor in this untested regulatory system and enable the entity to be a though leader in this space</li> <li>3. Strong and diverse professional team</li> <li>4. In a position to reframe the regulatory footprint in Africa</li> <li>5. Sound strategic partnerships that advance the mandate of SAHPRA</li> <li>6. Established key collaborations and memberships, such as AMRH, Zazibona and PIC/s, WHO Collaborative Review Process</li> </ol>		<ol style="list-style-type: none"> <li>1. No quality management in place to fortify system changes and governance</li> <li>2. Lack of a digitised track and trace system, including cost center and revenue</li> <li>3. Critical positions filled by acting managers</li> <li>4. Lack of skilled staff to support the programme changed business processes</li> <li>5. Low staff morale with regard to transition and extensive change, with no staff climate surveys conducted. As yet, no proper human resource change management processes rolled out to support staff</li> <li>6. Shortage of skilled assessors</li> <li>7. Heavy reliance on external reviewers</li> <li>8. Non-competitive remuneration policies allowing for benchmarking exercises</li> <li>9. Inability to confirm which of the vacant positions are actually funded</li> <li>10. A lack of fees review around business processes has resulted in loss of revenue from not collecting fees or not collecting adequate fees to match the cost of business processes</li> <li>11. No way of confirming effectiveness of renewed performance review systems</li> </ol>



OPPORTUNITIES	THREATS
<ol style="list-style-type: none"> <li>1. SAHPRA is in a position to grow despite an adverse economy as operational efficiency will stimulate higher fees</li> <li>2. Improved efficiencies through digitisation</li> <li>3. Change in legislation to accommodate reliance arrangements</li> <li>4. Lessons of experience of backlog clearance project and other Authorities</li> <li>5. As a Schedule 3A, SAHPRA can now inculcate a new SAHPRA corporate culture underpinned by professionalism</li> <li>6. Opportunity to secure donor funding as a schedule 3A entity</li> <li>7. An opportunity to create a fee structure to generate more revenue necessary for financial sustainability</li> <li>8. Implementing renewed performance review system both for management and staff to improve individual performance and consequence management</li> <li>9. Establishing a framework for regular and efficient interactions with all stakeholders and partner agencies</li> <li>10. Conducting independent stakeholder surveys</li> </ol>	<ol style="list-style-type: none"> <li>1. There is currently no documented process that regulates the working relationship between the Department of Health and SAHPRA. Shareholder Compacts are not legislated for Section 3A entities but there are no preclusions</li> <li>2. Poaching of staff from the industry remains a threat during the period of uncertainty in the transition</li> <li>3. Current internal capacity challenges could lead to a creation of a new backlog</li> <li>4. Fraud and corruption risks if internal audit is not fortified</li> <li>5. Flight of scarce skills with increased professional emigration out of South Africa</li> <li>6. Reliance on external expertise if skills transfer from senior experts is not facilitated in an active process of knowledge transfer</li> <li>7. Low staff morale</li> <li>8. No proper change management</li> <li>9. Lack of funding expected to support the backlog project</li> <li>10. Diminished revenue due to inadequate fees increase in the last three years</li> <li>11. Treasury cuts leading to diminished fiscus, with government austerity measures currently underway</li> <li>12. Inordinate pressure from the industry stakeholder threatens to sift SAHPRA's focus from its Public Health mandate towards an industry agenda if not managed properly</li> </ol>

## 1.2 Internal Environment Analysis

### Proposed Amendments to the Medicines Act

The Medicines and Related Substances Act, (101 of 1965) as amended has been in place since 1965. The Act has been amended several times to close critical gaps that existed at the time, with the last amendment being made in 2015. Since the SAHPRA Board came into office in January 2018, no amendments have been effected. SAHPRA has noted the following amendments that will be addressed in 2021:

1. Some definitions need clarification such as;
2. New definitions need to be inserted;
3. Some sections of the Act are not arranged in an orderly fashion and this has led to confusion and interpretation challenges;
4. Some sections may have to be repealed;

5. Some sections of the Act are incomplete and need to be expanded on fully;
6. Some chapters of the Act require clarification and/or strengthening;
7. New sections must be introduced;
8. The Act should be aligned and consistent for proper administration of the Act; and
9. New regulations must be introduced.

It is anticipated that a complete overhaul of the Medicines Act will be implemented in 2021. This will focus on aspects as such introducing new section that focus on Medical devices and IVDs as well as sections creating harmonization with the hazardous substances Act.

### **Human Resources**

The timely filing of vacant positions in SAHPRA is a priority as this an impact on the delivery of its services. SAHPRA has prioritised the filing of posts into the following categories: critical, core and scarce business positions. Sufficient capacity has been established by the availability of the administration staff from the NDoH transferred to SAHPRA as per the Labour Relations Act, Section 197 process. The transition of employees transferred from the NDoH to SAHPRA will be completed by placing them in the organisational structure. In addition, all the executive positions have been filled and this will expedite the filling of all vacancies in the various programmes.

As a new institution and a learning organisation, the training and development of employees will also be prioritised. A culture of high performance will be instilled through implementing the change management interventions. To drive successful performance, SAHPRA will improve the implementation of the Performance Management System.

### **Information and Communication Technology**

SAHPRA's digital transformation is a priority as the focus is on building capabilities and systems that will allow the institution to be more agile, innovative, streamlined, efficient in the delivery of its mandate. At the center of this digitisation will be intuitive self -service customer portals for the end user, as well as intelligent internal management and review systems to streamline the entire regulatory process.

The potential of digitalisation has already been tested in SAHPRA with the introduction of a number of digital platforms such as the Electronic Document Submission System, Digital Variations Portal and the Complimentary Medicines Licensing Portal, amongst others.

The introduction of the various information technology (IT) initiatives has allowed employees to work remotely during the COVID-19 pandemic. What is encouraging is that remote working has resulted in increased productivity for core business but also resulted in SAHPRA incurring high data costs for employees to access the IT systems remotely.

The development of an integrated Regulatory Information Management System will be a flagship project for the digital transformation of SAHPRA, bringing all regulatory processes onto one platform with the built-in automation, intelligence and powerful report capabilities.

### **Financial Resources**

The South African government faces fiscus constraints which has impacted on the funding SAHPRA receives from National Treasury. SAHPRA as a recently established public entity has a significant expenditure as compared to an established entity. The combination of a decreased fiscus-funding and the significant expenditures will continue to challenge SAHPRA while stabilising as a fledgling schedule 3A entity and moving seamlessly out of the current transitional operational environment.

Management is acutely aware of the need to innovatively match the available resources to priorities that maximize outputs whilst keeping in mind the significant opportunities to boost earnings revenue from the provision of a range of services such as registering medical devices and licensing of radioactive nuclides. SAHPRA is aiming to achieve an unqualified audit in the coming financial years wherein measures have been implemented to this end including improved management oversight, increased policy and procedure clarity, investments in training and development as well as a focus on adequate staffing. SAHPRA is in the process of automation of mundane tasks and integration of key activities which will create substantial efficiencies and liberate valuable time that could be redirected to high-end value-added activities.

## Overview of 2021/2022 Budget and Medium Term Expenditure Framework Estimates

### Summary of the Medium Term Expenditure Framework Budget

SUMMARY OF ECONOMIC CLASSIFICATION OF PAYMENTS	Current Year Budget	Medium Term Estimates		
	2020/21	2021/22	2022/23	2023/24
	R'000	R'000	R'000	R'000
<b>REVENUE</b>	<b>387,763</b>	<b>357,550</b>	<b>322,899</b>	<b>336,586</b>
- Fees	196,771	162,264	168,755	179,666
- Interest received	6,000	3,999	4,179	4,367
- Deferred income	25,840	45,000		
- Treasury allocation	159,152	146,287	149,965	152,553
<b>TOTAL CURRENT PAYMENTS</b>	<b>387,763</b>	<b>357,550</b>	<b>322,899</b>	<b>336,586</b>
Compensation of employees	215,772	185,177	187,156	194,369
Goods and services	171,991	172,373	135,743	142,217
<b>TOTAL PAYMENTS</b>	<b>387,763</b>	<b>357,550</b>	<b>322,899</b>	<b>336,586</b>
<b>Excess / (shortfall)</b>		-	-	-

### Budget per programme

Programme	Current Year Budget	Medium Term Estimates (SAHPRA)		
	2020/21	2021/22	2022/23	2023/24
	R'000	R'000	R'000	R'000
1) Administration	137,985	116,510	113,222	118,884
2) Authorisation management	69,098	72,534	32,595	33,636
3) Inspectorate and regulatory compliance	38,504	35,827	38,630	40,221
4) Medicines evaluation and registration	88,217	92,962	97,139	101,078
5) Devices and radiation control	53,959	39,717	41,312	42,767
	<b>387,763</b>	<b>357,550</b>	<b>322,899</b>	<b>336,586</b>

### Fees

During the 2019/20 financial year, the Board approved the review of SAHPRA fees. The fees had not been reviewed since 2017. Recommendations were made to the Minister of Health and the revised fees were published for comment in June 2020. The comments were considered by SAHPRA and further recommendations were made to the Minister of Health. These fees would be implemented in the later part of the 2020/21 financial year.

There is currently a significant opportunity to boost earnings revenue from the provision of a range of services such as registering medical devices and licensing of electronic generators of radiation and radionuclides. The frameworks to efficiently regulate these sectors has not come to full fruition due to a lack of internal processes, other internal constraints and competing business priorities such as

eradicating the backlog and re-engineering of the business-as-usual operations. Thus, as the organisation reviews its fees, the services relating to medical devices, radiation control and complementary medicines, among others, will be developed.

#### **Status of compliance with the Broad-Based Black Economic Empowerment Act**

During the 2020/21 financial year, SAHPRA had a series of engagements with the Broad-Based Black Economic Empowerment Commission. The purpose of the engagements was to seek alignment on the status of SAPHRA's BEE compliance. A legal opinion on how SAHPRA should comply with BEE legislation was sourced. The Board will hold further deliberations on the implementation of the recommendations in the later part of the 2020/21 financial year. It is expected that these recommendations will be implemented from 2021/22 financial year.

## PART C: MEASURING OUR PERFORMANCE

### 1. INSTITUTIONAL PROGRAMME PERFORMANCE INFORMATION

#### 1.1 Programme 1: Leadership and Support

**Purpose:** To provide the leadership and administrative support necessary for SAHPRA to deliver on its mandate and comply with all legislative requirements.

##### 1.1.1 Sub-programmes

Sub-Programme	Purpose
Financial and Supply Chain Management	To serve all business units in SAHPRA, the senior management team and the Board by maintaining an efficient, effective and transparent system of financial, and risk management that complies with the applicable legislation
Governance and Compliance	To provide support services and ensure compliance with relevant legislation; and achieve an unqualified audit outcome by ensuring continuous management practices through compliance with standards operating procedures and systems within SAHPRA. Further, to review existing operational processes and recommend new or changed processes and work methods to ensure optimal organisational effectiveness and, measure and monitor the Authority's performance
Information Technology and Communication (ICT)	to develop and implement ICT integrated governance framework by focusing on the business continuity plan and support the needs and requirements of the end users. Further, to manage public relations, information and communication services to ensure proper management and dissemination of information to internal and external stakeholders, to ensure a seamless harmonious operational platform by building strong and sustainable relationships with all its stakeholders
Human Resource Management	To provide human resources and organisational development systems and solutions that meet the needs of the organisation and support the achievement of the Authority's strategic objectives

### 1.1.2 Outcomes, Outputs, Output Indicators and Targets

OUTCOMES	OUTPUTS	OUTPUT INDICATORS	AUDITED/ACTUAL PERFORMANCE			ESTIMATED PERFORMANCE 2020/21	No.	MEDIUM TERM EXPENDITURE FRAMEWORK TARGETS		
			2017/18	2018/19	2019/20			2021/22	2022/23	2023/24
Effective financial management (1)	Attain and maintain an unqualified overall AG Audit outcome on previous year's performance	Unqualified audit opinion obtained on the annual financial statements	-	Qualified audit opinion	Qualified audit outcome	Unqualified audit opinion	1.1	Unqualified audit opinion obtained	Unqualified audit opinion obtained	Unqualified audit opinion obtained
Financial sustainability achieved through revenue generated and enhanced operational efficiencies (2)	Total revenue generated from fees	Total revenue generated from fees in the financial year	-	-	R21.3 million	R387 million	1.2	Revenue of R162 million generated from fees	Revenue of R169 million generated from fees	Revenue of R175 million generated from fees
	Break-even of expenses and revenue by 31 March	Break-even of expenses and revenue by 31 March	-	-	Surplus of R31.1 million	≥ zero based balance	1.3	Zero	Zero	Zero
Continuously respond to the needs and expectations of SAHPRA stakeholders (3)	Recommendations implemented	Percentage of prioritised recommendations from the survey implemented	-	-	-	-	1.4	40% prioritised recommendations from the survey implemented	60% prioritised recommendations from the survey implemented	80% prioritised recommendations from the survey implemented



OUTCOMES	OUTPUTS	OUTPUT INDICATORS	AUDITED/ACTUAL PERFORMANCE			ESTIMATED PERFORMANCE 2020/21	No.	MEDIUM TERM EXPENDITURE FRAMEWORK TARGETS		
			2017/18	2018/19	2019/20			2021/22	2022/23	2023/24
A positive and enabling working culture created (4)	Change management intervention implemented	Percentage of the change management intervention implemented	-	-	-	-	1.5	50% of the change management intervention implemented	80% of the change management intervention implemented	100% of the change management intervention implemented
	Workplace Skills Plan implemented	Percentage of the Workplace Skills Plan implemented	-	-	-	-	1.6	30% of the Workplace Skills Plan implemented	60% of the Workplace Skills Plan implemented	100% of the Workplace Skills Plan implemented
Attract and retain superior talent (5)	Percentage of positions filled	Percentage of positions in the staff establishment filled	-	-	76%	100% of prioritised positions filled	1.7	60% budgeted positions filled	80% budgeted positions filled	90% budgeted positions filled
Strengthened Information and Communication Technology and digitisation (6)	9 business processes digitalised	Number of business processes digitalised	-	-	-	60% digitisation of SAHPRA processes	1.8	3 business processes digitalised	3 business processes digitalised	3 business process digitalised

### 1.1.3 Output Indicators: Annual and Quarterly Targets

OUTPUT INDICATORS	No.	2021/22 ANNUAL TARGETS	1 <sup>ST</sup> QUARTER TARGETS (Apr - Jun)	2 <sup>ND</sup> QUARTER TARGETS (Jul - Sep)	3 <sup>RD</sup> QUARTER TARGETS (Oct - Dec)	4 <sup>TH</sup> QUARTER TARGETS (Jan - Mar)
Unqualified audit opinion obtained on the annual financial statements	1.1	Unqualified audit opinion obtained	Annual financial statements prepared	Unqualified audit opinion obtained	Quarterly financial reports prepared	Quarterly financial reports prepared
Total revenue generated from fees in the financial year	1.2	Revenue of R162 million generated from fees	Revenue of R56 million generated from fees	Revenue of R56 million generated from fees	Revenue of R25 million generated from fees	Revenue of R25 million generated from fees
Break-even of expenses and revenue by 31 March	1.3	Zero	Zero	Zero	Zero	Zero
Percentage of prioritised recommendations from the survey implemented	1.4	40% prioritised recommendations from the survey implemented	10% prioritised recommendations from the survey implemented	20% prioritised recommendations from the survey implemented	30% prioritised recommendations from the survey implemented	40% prioritised recommendations from the survey implemented
Change management intervention implemented	1.5	50% of the change management intervention implemented	15% of the change management intervention implemented	25% of the change management intervention implemented	40% of the change management intervention implemented	50% of the change management intervention implemented
Workplace Skills Plan implemented	1.6	30% of the Workplace Skills Plan implemented	10% of the Workplace Skills Plan implemented	15% of the Workplace Skills Plan implemented	25% of the Workplace Skills Plan implemented	30% of the Workplace Skills Plan implemented
Percentage of positions filled	1.7	60% budgeted positions filled	25% budgeted positions filled	35% budgeted positions filled	50% budgeted positions filled	60% budgeted positions filled
9 business processes digitalised	1.8	3 business processes digitalised	-	1 business process digitalised	1 business process digitalised	1 business process digitalised

### **1.1.4 Explanation of Planned Performance over the Medium Term Period**

#### **Finance**

Focus over the medium term will be placed on improving management oversight, increasing policy and procedure clarity, investing in training and development as well as an adequate staffing. The automation of mundane tasks and the integration of key activities will improve the SAHPRA's operational efficiency and service delivery. The planned performance over the medium-term will directly contribute to SAHPRA's outcome of attaining sustainable public finances, sound financial control and management of public finances.

#### **Communications**

The annual survey recommendations will be implemented and monitored by the different business units to ensure stakeholder satisfaction. A web query mechanism is already in place and the results of the queries and resolution will be disseminated to business units.

IT will advise on a ticketing system to ensure that queries and complaints are addressed. Once the staff perception survey has been completed, HR and Communication will work together on change management initiatives. This will commence after the internal transfer process as well as the recruitment process.

#### **Human Resources**

The timely filling of vacant positions in SAHPRA is a priority as this has an impact on the delivery of its services. SAHPRA has prioritised the filling of posts into the following categories: critical, core and scarce business positions. Sufficient capacity has been established by the availability of the administration staff from the NDoH transferred to SAHPRA as per the Labour Relations Act, Section 197 process. The transition of employees transferred from the NDoH to SAHPRA will be completed by placing them in the organisational structure. In addition, all the executive positions have been filled and this will expedite the filling of all vacancies in the various programmes.

As a new institution and a learning organisation, the training and development of employees will also be prioritised. A culture of high performance will be instilled through implementing the change management interventions. To drive successful performance, SAHPRA will improve the implementation of the Performance Management System.

## Information Technology

The digital transformation process will be Setout in a detailed roadmap that will guide the prioritisation, deployment as well as the enhancement of the core business processes within SAHPRA, with the emphasis being on supporting the strategic imperatives of SAHPRA over the short and long term.

In the short-term, IT will continue to innovate and address low hanging business challenges to add responsiveness where there are challenges.

### 1.1.5 Programme Resource Considerations

*Resource considerations (R'000)*

2018/19	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24
Budget Estimates	Audited Outcome	Audited Outcome	Budget Estimates	Budget Estimates	Budget Estimates	Budget Estimates
<i>No historical data - New public entity</i>	79,973	79,842	137,985	116,510	113,222	118,884
<b>Economic Classification of Budget</b>	79,973	79,842	137,985	116,510	113,222	118,884
Compensation of Employees	41,315	44,611	47,090	48,922	46,473	47,933
Goods and Services	8,546	32,961	89,038	67,588	66,749	70,951

## 1.2 Programme 2: Health Products Authorisation

**Purpose:** To provide administration support necessary for SAHPRA to deliver on its mandate and comply with the relevant legislative requirements. The specific purpose of this programme is to coordinate the process of registration and/or licensing or amendment of applications in respect of medicines within a legislative framework that defines the requirements necessary for application to the Authority, to receive record and distribute all documents submitted to SAHPRA.

### 1.2.1 Sub-programmes

Sub-Programme	Purpose
Document reception and helpdesk	The purpose of this sub-programme is to receive, record and/or direct all documents submitted to SAHPRA
Project office – regulatory decision for medicines	The purpose is to coordinate the process of the making of a regulatory decision of medicines (screening, dispatch to evaluators, coordinating reports, recommendations, responses, arranging peer and product review meetings). It is also involved in ensuring that regulatory decisions made at the time of registration are in the public interest throughout the products' lifecycle through post-marketing vigilance of registered products. Vigilance includes the soliciting of data through various approaches, monitoring, analysis and responsive action, including the provision of feedback. In addition, a fully staffed backlog project team led by a senior project manager and linked to this sub-programme will be established
Project office – clinical trials, section 21 portfolio management	The purpose is to coordinate the vigilance process and authorisation of clinical trials and Section 21 applications for medicines and devices within a legislative framework that defines the requirements necessary for application to the Authority. Details on the assessment procedure and the grounds for approval or rejection of the application, and also the circumstances where authorisation already granted may be cancelled, withdrawn, suspended or revoked, are also catered for
Licensing, permits and certificates portfolio management	The purpose is to manage and coordinate the process of licensing and amendments in respect of medicines manufacturers, wholesalers and medical device establishments and the issue of permits and registration certificates within a legislative framework that defines the requirements necessary for application to the Authority. Details on the assessment procedure (based on quality, efficacy and safety criteria) and the grounds for approval or rejection of the application, and also the circumstances where registration/licence/authorisation already granted may be cancelled, withdrawn, suspended or revoked, are also catered for

### 1.2.2 Outcomes, Outputs, Output Indicators and Targets

OUTCOMES	OUTPUTS	OUTPUT INDICATORS	AUDITED/ACTUAL PERFORMANCE			ESTIMATED PERFORMANCE 2020/21	No.	MEDIUM TERM EXPENDITURE FRAMEWORK TARGETS		
			2017/18	2018/19	2019/20			2021/22	2022/23	2023/24
High levels of organisational operational efficiency and effectiveness in the regulatory function maintained (7)	Backlog in medicine registration cleared	Percentage of medicine registrations in the backlog cleared	-	-	58%	40% applications for registration cleared	2.1	95% medicine registrations backlog cleared	100% medicine registrations backlog cleared	-
	Backlog in medicine variation applications cleared	Percentage of medicine variation applications in the backlog cleared	-	-	58%	90% variation applications cleared	2.2	95% medicine variation applications backlog cleared	100% medicine variation applications backlog cleared	-
	New Chemical Entities applications finalised	Percentage of New Chemical Entities finalised within 590 working days	-	-	100%	60% in 590 days	2.3	80% New Chemical Entities finalised within 590 working days	80% New Chemical Entities finalised within 490 working days	80% New Chemical Entities finalised within 400 working days
	Generic medicines applications finalised	Percentage of generic medicines finalised within 250 working days	-	-	-	60% in 250 days	2.4	60% generic medicines finalised within 250 working days	80% generic medicines finalised within 250 working days	95% generic medicines finalised within 250 working days

OUTCOMES	OUTPUTS	OUTPUT INDICATORS	AUDITED/ACTUAL PERFORMANCE			ESTIMATED PERFORMANCE 2020/21	No.	MEDIUM TERM EXPENDITURE FRAMEWORK TARGETS		
			2017/18	2018/19	2019/20			2021/22	2022/23	2023/24
	Quality Management System Requirements implemented	Percentage of the Quality Management System requirements implemented	-	-	-	Medicines Regulatory Quality Management system developed and implemented	2.5	40% Quality Management System requirements implemented	60% Quality Management System requirements implemented	80% Quality Management System requirements implemented
Global best practices maintained (8)	WHO global benchmarking conducted	WHO maturity level obtained benchmark level	-	-	-	Maturity level 3	2.6	WHO maturity level 3 obtained	WHO maturity level 3 maintained	WHO maturity level 4 obtained



### 1.2.3 Output Indicators: Annual and Quarterly Targets

OUTPUT INDICATORS	No.	2021/22 ANNUAL TARGETS	1 <sup>ST</sup> QUARTER TARGETS (Apr - Jun)	2 <sup>ND</sup> QUARTER TARGETS (Jul - Sep)	3 <sup>RD</sup> QUARTER TARGETS (Oct - Dec)	4 <sup>TH</sup> QUARTER TARGETS (Jan - Mar)
Percentage of medicine registrations backlog cleared	2.1	95% medicine registrations backlog cleared	49% medicine registrations backlog cleared	69% medicine registrations backlog cleared	89% medicine registrations backlog cleared	95% medicine registrations backlog cleared
Percentage of medicine variation applications backlog cleared	2.2	95% medicine variation applications backlog cleared	90% medicine variation applications backlog cleared	92% medicine variation applications backlog cleared	93% medicine variation applications backlog cleared	95% medicine variation applications backlog cleared
Percentage of New Chemical Entities finalised within 590 working days	2.3	80% New Chemical Entities finalised within 590 working days	80% New Chemical Entities finalised within 590 working days	80% New Chemical Entities finalised within 590 working days	80% New Chemical Entities finalised within 590 working days	80% New Chemical Entities finalised within 590 working days
Percentage of generic medicines finalised within 250 working days	2.4	60% generic medicines finalised within 250 working days	60% generic medicines finalised within 250 working days	60% generic medicines finalised within 250 working days	60% generic medicines finalised within 250 working days	60% generic medicines finalised within 250 working days
Percentage of the Quality Management System requirements implemented	2.5	40% Quality Management System requirements implemented	Training on the implementation of the business processes for all programmes conducted	Draft report on the Quality Management System audits produced	Management review of the implementation of the Quality Management System conducted	40% Quality Management System requirements implemented
WHO maturity level obtained benchmark level	2.6	WHO maturity level 3 obtained	WHO assisted assessment conducted	Report on the implementation of the Institutional Development Plan developed	Final WHO assessment conducted	WHO maturity level 3 obtained

### 1.2.4 Explanation of Planned Performance over the Medium Term Period

#### Backlog

Focus over the medium term will be placed on streamlining and expediting piloted review approaches, such as Abridged and Verified review (with specific focus on internal reliance for the latter). In support of this, there will be an increase in policy and procedure clarity, with the assistance of QMS. Performance management of evaluators is to form a core part of the activities, in part to ensure alignment with current SAHPRA strategies. Risk-based evaluation assessment practices to be reviewed and, if feasible, to be implemented. It is envisaged that these interventions will improve turnaround-times and accessibility to medicines. Furthermore, enhanced collaboration between SAHPRA and other medicines regulators (both regional and international) will remain a focus and solutions garnered by other agencies in terms of clearance of an application backlog will be considered within the SAHPRA backlog scenario.

#### Medicines Registration

Medicines are registered through a process of rigorous review of quality, safety and efficacy data submitted. Reviews for registrations are of two types namely new chemical entities (NCE's) and generic medicines. The NCE's are often novel drugs that may be medicines used for unmet medical needs and can include oncology medicines, these often involve extensive clinical review and quality review of synthesis of novel agents. Generics forms the bulk of the applications received and can be extensive for quality and bioequivalence reviews whereas the clinical is based on the already registered innovator and would involve less rigorous clinical review.

The medium-term objectives aims to reduce review timelines with NCE and to improve the percentage generics registered within expected timelines. This is anticipated to be achieved through using efficiencies such as reliance on reviews conducted by National Regulatory Authorities with which SAHPRA aligns with as well as through regulatory collaborations such as WHO PQ and Zazibona (SADC) where joint reviews take place hence optimising on the resources (evaluators) we have. The efficiency over this period is envisaged to improve as additional staff are to be recruited and further all staff are trained in various areas of review to enable increased flexibility in reviews as well as build SAHPRA internal review capacity in this period. Efficiencies are also envisaged to improve with digitization and implementation of an integrated management systems as well as an implemented quality management system which will enable less time to be spent on manual systems currently used for generating reports.

## Quality Management System

The implementation of the Quality Management System (QMS) is an integral part of creating uniformity, improve efficiency of SAHPRA processes and customer satisfaction. Effective implementation of QMS further supports SAHPRA objective of achieving maturity level 3. QMS is one of the indicators in the WHO global benchmarking tool. SAHPRA Quality Management Systems will be subjected to regular assessment, audits and management reviews for continuous improvement. Details of the Quality Management System will be documented in the Quality Manual which among other things will state the Quality Policy Statement, Mission and Quality Objectives.

## WHO Maturity

SAHPRA is targeting to be at WHO maturity level 3 (ML3) where core regulatory functions will be operational and meet the criteria and standards set. The Authority will conduct annual WHO Global Benchmarking self-assessments and final WHO assessments to reach ML3. Furthermore, SAHPRA will develop and Implement the Institutional Development Plan, addressing identified gaps and interventions required as per the WHO Global Benchmarking Tool to strive for the desired long term target of reaching maturity level 4.

### 1.2.5 Programme Resource Considerations

*Resource considerations (R'000)*

2018/19	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24
Budget Estimates	Audited Outcome	Audited Outcome	Budget Estimates	Budget Estimates	Budget Estimates	Budget Estimates
<i>No historical data - New public entity</i>	18,578	28,883	69,098	72,534	32,595	33,636
<b>Economic Classification of Budget</b>	18,578	28,883	69,098	72,534	32,595	33,636
Compensation of Employees	14,020	16,812	35,354	22,382	22,534	23,275
Goods and Services	4,558	12,071	33,744	50,152	10,061	10,361

### 1.3 Programme 3: Inspectorate and Regulatory Compliance

**Purpose:** To ensure public access to safe health products (include disclaimer) through inspections and regulatory compliance. The focus of this programme includes assessment of site compliance, with good regulatory and vigilance practices, including:

- Good Manufacturing Practice (GMP);
- Good Clinical Practice (GCP);
- Good Warehouse Practice (GWP);
- Good Distribution Practice (GDP);
- Good Laboratory Practice (GLP);
- Good Vigilance Practice (GVP)

#### 1.3.1 Sub-programmes

Sub-Programme	Purpose
Inspections	To ensure that GxP's inspection activities are actively managed to facilitate the running of an effective inspection programme monitored against pre-defined timelines and commitments communicated to stakeholders
Regulatory Compliance	To ensure public access to safe medicines through regulatory compliance and monitoring of compliance with applicable legislation as mandated

### 1.3.2 Outcomes, Outputs, Output Indicators and Targets

OUTCOMES	OUTPUTS	OUTPUT INDICATORS	AUDITED/ACTUAL PERFORMANCE			ESTIMATED PERFORMANCE 2020/21	No.	MEDIUM TERM EXPENDITURE FRAMEWORK TARGETS		
			2017/18	2018/19	2019/20			2021/22	2022/23	2023/24
High levels of organisational operational efficiency and effectiveness in the regulatory function maintained (7)	New GMP and GWP related licences finalised	Percentage of new GMP and GWP related licenses finalised within 125 working days	-	-	77%	50% of licenses issued for new applications within predetermined timeline	3.1	60% new GMP and GWP related licenses finalised within 125 working days	75% new GMP and GWP related licenses finalised within 125 working days	80% new GMP and GWP related licenses finalised within 125 working days
	Permits finalised	Percentage of permits finalised within 20 working days	-	-	95%	-	3.2	70% permits finalised within 20 working days	75% permits finalised within 20 working days	80% permits finalised within 20 working days
	Health product quality complaint reports	Percentage of health product quality complaint reports produced within 30 working days	-	-	70%	60% of health product quality complaints investigated	3.3	70% health product quality complaints reports produced within 30 working days	80% health product quality complaints reports produced within 30 working days	90% health product quality complaints reports produced within 30 working days

### 1.3.3 Output Indicators: Annual and Quarterly Targets

OUTPUT INDICATORS	No.	2021/22 ANNUAL TARGETS	1 <sup>ST</sup> QUARTER TARGETS (Apr - Jun)	2 <sup>ND</sup> QUARTER TARGETS (Jul - Sep)	3 <sup>RD</sup> QUARTER TARGETS (Oct - Dec)	4 <sup>TH</sup> QUARTER TARGETS (Jan - Mar)
Percentage of new GMP and GWP related licenses finalised within 125 working days	3.1	60% new GMP and GWP related licenses finalised within 125 working days	-	60% new GMP and GWP related licenses finalised within 125 working days	-	60% new GMP and GWP related licenses finalised within 125 working days
Percentage of permits finalised within 20 working days	3.2	70% permits finalised within 20 working days	70% permits finalised within 20 working days	70% permits finalised within 20 working days	70% permits finalised within 20 working days	70% permits finalised within 20 working days
Percentage of health product quality complaint reports produced within 30 working days	3.3	70% health product quality complaints reports produced within 30 working days	70% health product quality complaints reports produced within 30 working days	70% health product quality complaints reports produced within 30 working days	70% health product quality complaints reports produced within 30 working days	70% health product quality complaints reports produced within 30 working days

### 1.3.4 Explanation of Planned Performance over the Medium Term Period

Licences, permits and the investigation of quality complaints are mechanisms to exercise regulatory control in order to attain and maintain the desired levels of industry compliance in the quest to safeguard the safety of medicines of all those that live in South Africa. This is one of the fundamentals necessary for SAHPRA to achieve its organisational impact.

As Good Manufacturing Practice related and Good Warehouse Practice related licenses are only issued to South African manufacturers, importer/exporters and wholesalers, the focus on processing and finalising new applications contributes to the increase in local pharmaceutical industry economic activity.

With the risk of illicit, substandard or falsified medicine, the timeous investigation of product quality complaints ensures that any detected risk is resolved, and persons involved are held accountable.

The planned performance targets are planned to increase over the medium term as efficiencies are driven by improving internal processes and adequate resource use.

### 1.3.5 Programme Resource Considerations

*Resource considerations (R'000)*

2018/19	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24
Budget Estimates	Audited Outcome	Audited Outcome	Budget Estimates	Budget Estimates	Budget Estimates	Budget Estimates
<i>No historical data - New public entity</i>	35,379	40,026	38,504	35,827	38,630	40,221
<b>Economic Classification of Budget</b>	35,379	40,026	38,504	35,827	38,630	40,221
Compensation of Employees	24,210	26,495	24,760	31,300	32,424	33,835
Goods and Services	11,169	13,531	13,744	4,527	6,206	6,386

## 1.4 Programme 4: Clinical and Pharmaceutical Evaluation

**Purpose:** To evaluate the safety, quality and therapeutic efficacy of medicines and register them for use as per delegated authority in terms of relevant legislation as listed in the legal mandate of part 1a of the strategic plan.

### 1.4.1 Sub-programmes

Sub-Programme	Purpose
Clinical Evaluation	To evaluate the safety and efficacy of orthodox medicines
Clinical Trials	To evaluate clinical trial applications of orthodox medicines, complementary medicines and medical devices to ensure that the trial to be conducted is scientifically sound in accordance with the South African Good Clinical Practice guidelines and to ensure safety and protection of rights of patients
Pharmaceutical Evaluations	To perform pharmaceutical and analytical evaluations of new and registered medicines inclusive of clinical aspects of veterinary medicines and biological
Authorisation of the Sale of Unregistered Medicines	To conduct an abbreviated evaluation of applications to authorise the sale of unregistered medicines based on QSE standards
Vigilance and Post-Marketing Surveillance	To establish a regimen of vigilance for the collection and evaluation of information relevant to the benefit to risk balance of medicines and medical devices on the South African market, the continuous monitoring of the safety profiles of these products and taking appropriate action where necessary
Complementary and Alternative Medicines	To perform evaluations of new and registered complementary medicines in order to determine their safety, quality and efficacy and to register and/or regulate them for use where applicable
Veterinary Medicines	To evaluate the safety, efficacy and quality of veterinary medicines



### 1.4.2 Outcomes, Outputs, Output Indicators and Targets

OUTCOMES	OUTPUTS	OUTPUT INDICATORS	AUDITED/ACTUAL PERFORMANCE			ESTIMATED PERFORMANCE 2020/21	No.	MEDIUM TERM EXPENDITURE FRAMEWORK TARGETS		
			2017/18	2018/19	2019/20			2021/22	2022/23	2023/24
High levels of organisational operational efficiency and effectiveness in the regulatory function maintained (7)	Applications for the sale of unregistered Category A (human) medicines finalised	Percentage applications for the sale of unregistered Category A (human) medicines finalised within 24 working hours	-	-	96%	85% applications for the sale of unregistered Category A (human) medicines finalised within 24 working hours	4.1	85% applications for the sale of unregistered Category A (human) medicines finalised within 24 working hours	85% applications for the sale of unregistered Category A (human) medicines finalised within 24 working hours	85% applications for the sale of unregistered Category A (human) medicines finalised within 24 working hours
	Human clinical trial applications finalised	Percentage of human clinical trial applications finalised within 90 working days	-	-	100%	80% human clinical trial applications finalised within 120 working days	4.2	80% human clinical trial applications finalised within 90 working days	80% human clinical trial applications finalised within 60 working days	80% human clinical trial applications finalised within 60 working days

OUTCOMES	OUTPUTS	OUTPUT INDICATORS	AUDITED/ACTUAL PERFORMANCE			ESTIMATED PERFORMANCE 2020/21	No.	MEDIUM TERM EXPENDITURE FRAMEWORK TARGETS		
			2017/18	2018/19	2019/20			2021/22	2022/23	2023/24
	Health product safety signals issued	Percentage of reports on health product safety signals issued within 40 working days	-	-	4	70% reports on health product safety signals actioned within 20 working days	4.3	70% reports on health product safety signals issued within 40 working days	70% reports on health product safety signals issued within 40 working days	70% reports on health product safety signals issued within 40 working days
	Safety awareness webinars held	Number of safety awareness webinars held	-	-	-	-	4.4	4 safety awareness webinars held	4 safety awareness webinars held	4 safety awareness webinars held

### 1.4.3 Output Indicators: Annual and Quarterly Targets

OUTPUT INDICATORS	No.	2021/22 ANNUAL TARGETS	1 <sup>ST</sup> QUARTER TARGETS (Apr - Jun)	2 <sup>ND</sup> QUARTER TARGETS (Jul - Sep)	3 <sup>RD</sup> QUARTER TARGETS (Oct - Dec)	4 <sup>TH</sup> QUARTER TARGETS (Jan - Mar)
Percentage applications for the sale of unregistered Category A (human) medicines finalised within 24 working hours	4.1	85% applications for the sale of unregistered Category A (human) medicines finalised within 24 working hours	85% applications for the sale of unregistered Category A (human) medicines finalised within 24 working hours	85% applications for the sale of unregistered Category A (human) medicines finalised within 24 working hours	85% applications for the sale of unregistered Category A (human) medicines finalised within 24 working hours	85% applications for the sale of unregistered Category A (human) medicines finalised within 24 working hours
Percentage of human clinical trial applications finalised within 90 working days	4.2	80% human clinical trial applications finalised within 90 working days	80% human clinical trial applications finalised within 90 working days	80% human clinical trial applications finalised within 90 working days	80% human clinical trial applications finalised within 90 working days	80% human clinical trial applications finalised within 90 working days
Percentage of reports on health product safety signals issued within 40 working days	4.3	70% reports on health product safety signals issued within 40 working days	70% reports on health product safety signals issued within 40 working days	70% reports on health product safety signals issued within 40 working days	70% reports on health product safety signals issued within 40 working days	70% reports on health product safety signals issued within 40 working days
Number of safety awareness webinars held	4.4	4 safety awareness webinars held	1 safety awareness webinar held	1 safety awareness webinar held	1 safety awareness webinar held	1 safety awareness webinar held

#### **1.4.4 Explanation of Planned Performance over the Medium Term Period**

##### **Sale of unregistered Category A (human) medicines**

SAHPRA's mandate includes ensuring timely access to safe, efficacious and quality health products to the South African public. However, some of these health products may not be registered in the Republic but are available in other markets. Therefore, the Medicines Act (Act 101 of 1965, as amended) provides for the sale of unregistered medicines and other health products on application to SAHPRA for unmet medical needs, where a registered alternative is either not available or does not meet the identified medical need. This is an important public health intervention that has to promptly ensure access to life-saving health products where these would otherwise not be available to prevent disease complications.

##### **Human clinical trials**

SAHPRA's mandate includes oversight of human clinical trials conducted within the Republic. This objective entails ensuring and facilitating efficient processing of clinical trial protocol applications and approving the conduct of clinical trials to enable timely access to health research and development within an environment that guarantees the safety of clinical trial participants.

##### **Health product safety signals**

SAHPRA's mandate includes monitoring the safety, efficacy, and quality of health products distributed and sold in the Republic. Such monitoring should be comprehensive and the response to any signals of declining safety and lack of clinical efficacy should be timely and evidence-based. To that end, the Programme has endeavoured to be highly responsive to such signals but, due to lack of resources, only the most serious and high public health impact signals have been concluded within the targeted 80 % in 20 working days timeframe.

##### **Health product safety awareness webinar**

Internationally, the rate of Adverse Drug Reaction (ADR) reporting is not more than 5%. The same applies to South Africa. One of the reasons is the lack of information, education and awareness about the need to report ADRs, to continuously monitor the safety and efficacy of medicines over the life of the product. Frequent outreach initiatives, such as public and targeted webinars will improve the awareness.

### 1.4.5 Programme Resource Considerations

Resource considerations (R'000)

2018/19	2018/19	2019/20	2020/21	2021/22	2022/23	2023/24
Budget Estimates	Audited Outcome	Audited Outcome	Budget Estimates	Budget Estimates	Budget Estimates	Budget Estimates
<i>No historical data - New public entity</i>	49,612	59,435	88,217	92,962	97,139	101,078
<b>Economic Classification of Budget</b>	49,612	59,435	88,217	92,962	97,139	101,078
Compensation of Employees	25,275	27,936	62,353	50,742	52,920	55,321
Goods and Services	24,337	31,499	25,864	42,220	44,219	45,757

## 1.5 Programme 5: Medical Devices and Radiation Control

**Purpose:** To develop and maintain regulations and guidelines pertaining to the regulatory oversight of medical devices, radionuclides, and listed electronic products.

### 1.5.1 Sub-programmes

Sub-Programme	Purpose
Medical Devices	To implement and strengthen the regulatory oversight of medical devices through the development and maintenance of relevant regulations and guidelines
Radiation Control	To efficiently, effectively and ethically evaluate and radionuclides and listed electronic products To protect patients, radiation workers, the public and the environment against possible adverse effects of ionizing radiation without limiting its beneficial uses

### 1.5.2 Outcomes, Outputs, Output Indicators and Targets

OUTCOMES	OUTPUTS	OUTPUT INDICATORS	AUDITED/ACTUAL PERFORMANCE			ESTIMATED PERFORMANCE 2020/21	No.	MEDIUM TERM EXPENDITURE FRAMEWORK TARGETS		
			2017/18	2018/19	2019/20			2021/22	2022/23	2023/24
High levels of organisational operational efficiency and effectiveness in the regulatory function maintained (7)	Medical device establishment licence applications finalised	Percentage of medical device establishment licence applications finalised within 90 days	-	-	99%	70% medical device establishment licence applications finalised within 90 days	5.1	70% medical device establishment licence applications finalised within 90 days	70% medical device establishment licence applications finalised within 90 days	80% medical device establishment licence applications finalised within 90 days
	Medical device registration regulations implemented	Medical device registration regulations implemented	-	-	-	Develop and Implement medical device registration framework	5.2	Guidelines to support the medical device registration regulations approved by the Executive Committee	10% call-up products registered	30% call-up products registered
	Radionuclide authorities finalised	Percentage of applications for radionuclide authorities finalised within 30 working days	-	-	99%	-	5.3	70% applications for radionuclide authorities finalised within 30 working days	70% applications for radionuclide authorities finalised within 30 working days	70% applications for radionuclide authorities finalised within 30 working days

OUTCOMES	OUTPUTS	OUTPUT INDICATORS	AUDITED/ACTUAL PERFORMANCE			ESTIMATED PERFORMANCE 2020/21	No.	MEDIUM TERM EXPENDITURE FRAMEWORK TARGETS		
			2017/18	2018/19	2019/20			2021/22	2022/23	2023/24
	Licence applications for listed-electronic products finalised	Percentage of licence applications for listed-electronic products finalised within 30 working days	-	-	-	-	5.4	70% licence applications for listed-electronic products finalised within 30 working days	70% licence applications for listed-electronic products finalised within 30 working days	70% licence applications for listed-electronic products finalised within 30 working days
	Co-Regulation Model	Approved Co-Regulation Model	-	-	-	-	5.5	Board approved Co-Regulation Model with the National Nuclear Regulator	-	-



### 1.5.3 Output Indicators: Annual and Quarterly Targets

OUTPUT INDICATORS	No.	2021/22 ANNUAL TARGETS	1 <sup>ST</sup> QUARTER TARGETS (Apr - Jun)	2 <sup>ND</sup> QUARTER TARGETS (Jul - Sep)	3 <sup>RD</sup> QUARTER TARGETS (Oct - Dec)	4 <sup>TH</sup> QUARTER TARGETS (Jan - Mar)
Percentage of medical device establishment licence applications finalised within 90 days	5.1	70% medical device establishment licence applications finalised within 90 days	70% medical device establishment licence applications finalised within 90 days	70% medical device establishment licence applications finalised within 90 days	70% medical device establishment licence applications finalised within 90 days	70% medical device establishment licence applications finalised within 90 days
Medical device registration regulations implemented	5.2	Guidelines to support the medical device registration regulations approved by the Executive Committee	Guidelines to support the medical device registration regulations submitted to the Executive Committee for review	Guidelines to support the medical device registration regulations approved by the Executive Committee	1 <sup>st</sup> phase call-up notices published	2 <sup>nd</sup> phase call-up notices published
Percentage of applications for radionuclide authorities finalised within 30 working days	5.3	70% applications for radionuclide authorities finalised within 30 working days	70% applications for radionuclide authorities finalised within 30 working days	70% applications for radionuclide authorities finalised within 30 working days	70% applications for radionuclide authorities finalised within 30 working days	70% applications for radionuclide authorities finalised within 30 working days
Percentage of licence applications for listed-electronic products finalised within 30 working days	5.4	70% licence applications for listed-electronic products finalised within 30 working days	70% licence applications for listed-electronic products finalised within 30 working days	70% licence applications for listed-electronic products finalised within 30 working days	70% licence applications for listed-electronic products finalised within 30 working days	70% licence applications for listed-electronic products finalised within 30 working days
Approved Co-Regulation Model	5.5	Board approved Co-Regulation Model with the National Nuclear Regulator	Terms of Reference approved	Draft Co-Regulation Model developed	Board approved Co-Regulation Model with the National Nuclear Regulator	-

## 1.5.4 Explanation of Planned Performance over the Medium Term Period

### Medical device establishment licences

The review and approval of medical device establishment licences are mechanisms implemented to exercise regulatory quality control over the manufacturers, distributors and wholesalers of medical devices to ensure products of the intended quality, safety and performance are either manufactured or imported into South Africa, and to attain and maintain the desired levels of industry compliance. Assessing the quantity of licence applications finalised in a particular year is a transparent indicator and true reflector of the level of compliance of medical device establishments in South Africa. This is one of the fundamentals necessary for SAHPRA to achieve its organisational impact. In addition as the licenses are only issued to South African manufacturers, importer/exporters and wholesalers, the assessment of licence applications contributes to the increase in local medical device industry economic activity.

The planned performance targets are planned to increase over the medium term as efficiencies are driven by improving internal processes and adequate resource use.

### Medical device registration regulations

The publication and implementation of the amended medical devices regulations enables the facilitation and development of the medical device registration pathways, which in turn enables the publication of the call-up for registration of medical device notices. In addition to the licensing mechanism (mentioned above in point), the registration of medical devices allows for additional regulatory control to ensure the quality, safety and performance of medical devices on the South African market.

The planned performance targets are planned to increase over the medium term as efficiencies are driven by improving internal processes and adequate resource use. The targets also change over the medium term as targets of framework development and guideline publications are met.

### Radiation control

The Medicines and Related Substances Act, 1965 (Act 101 of 1965) as amended, read in conjunction with the General Regulations on Medical Devices, published in Government Gazette Notice 40480, No.1515 of 9 December 2016, provides for the regulatory oversight of Medical Devices including *In-Vitro* Diagnostics in South Africa. The process of regulating medical devices only started in June 2017. When SAHPRA was established in 2018, it inherited the responsibility for the regulation of

radionuclides from NDoH. Currently, SAHPRA issues licenses for medical device establishments to importers, manufacturers, distributors and wholesalers.

The scope of work for SAHPRA includes the regulation of all applications of radiation protection used outside the nuclear fuel cycle in South Africa. This was done by inclusion of Group III and Group IV hazardous substances (as defined in Act 15 of 1973) into the definition of a medical device in Act 101 of 1965, as amended, in 2017. These include electromedical devices (Group III) and radionuclides and electronic generators of ionising radiation (Group IV). Regulation of these products is provided for by both the Medicines and Related Substances Act 101 of 1965, as amended and the Hazardous Substances Act, Act 15 of 1973 and its regulations.

SAHPRA has been holding engagements on the proposed transfer of some of the radiation control function from SAHPRA to the National Nuclear Regulator (NNR). The preferred model would be to retain the functions that have health and medical applications within SAHPRA and implement a co-regulation mechanism with the NNR. All those with industrial applications within Group II and IV would be wholly transferred to the NNR. A working group which will be appointed and jointly chaired by both the CEO of NNR and SAHPRA will be established, to amongst others, should develop a framework for co-regulation between the two entities as well as revise the draft cabinet memo to reflect this resolution.

This unit of SAHPRA is under resourced in terms of human resources and has staff nearing their retirement. SAHPRA will therefore put efforts to ensure that this critical unit is urgently capacitated with the critical skills sets required to meet the demands and ensure compliance with global treaties. SAHPRA will also continue to maintain the highest levels of protection of radiation workers, patients, public and the environment against the possible adverse effects of ionizing radiation without limiting its beneficial uses. Radiation control is conducted in accordance with international standards of the International Atomic Energy Agency.

## 1.5.5 Programme Resource Considerations

Resource considerations (R'000)

2018/19 Budget Estimates	2018/19 Audited Outcome	2019/20 Audited Outcome	2020/21 Budget Estimates	2021/22 Budget Estimates	2022/23 Budget Estimates	2023/24 Budget Estimates
No historical data - New public entity	16,695	22,231	53,959	39,717	41,312	42,767
<b>Economic Classification of Budget</b>	16,695	22,231	53,959	39,717	41,312	42,767
Compensation of Employees	14,247	15,746	46,215	31,831	32,804	34,005
Goods and Services	2,448	6,485	7,744	7,886	8,508	8,762

## 2. UPDATED KEY RISKS AND MITIGATION FROM THE STRATEGIC PLAN

OUTCOMES	KEY RISKS	RISK MITIGATIONS
Effective financial management (1)	Inadequate financial governance systems and processes resulting in unsustainable financial viability	<ol style="list-style-type: none"> <li>1. Conduct financial management training</li> <li>2. Review policies for alignment with GRAP standard</li> <li>3. Re-engineer and document Financial Management Policies and Processes</li> </ol>
Financial sustainability achieved through revenue generated and enhanced operational efficiencies (2)		
The needs and expectations of all SAHPRA stakeholders continuously met (3)	Negative perceptions about SAHPRA due to non-alignment with stakeholder needs	<ol style="list-style-type: none"> <li>1. Implementation of ICT Strategy for logging complaints, queries, etc.</li> <li>2. Conduct the annual independent survey for stakeholders needs</li> </ol>
A positive and enabling working culture created (4)	Difficulty in attracting and retaining talent	<ol style="list-style-type: none"> <li>1. Develop and implement roadmap (skill gaps audit) for capacity building program</li> <li>2. Development of workplace skills policy and plan</li> </ol>
Attract and retain superior talent (5)		

OUTCOMES	KEY RISKS	RISK MITIGATIONS
Strengthened Information and Communication Technology and digitisation (6)	Inability to invest in ICT infrastructure to enable automation and integration of SAHPRA processes	1. Establish ICT Governance policies, structures and processes
High levels of organisational operational efficiency and effectiveness in the regulatory function maintained (7)	Increasing backlog on new applications - Business as usual (BAU)	1. Continuous improvement of application process to improve turn - around time based on stakeholder feedback 2. Formalisation of strategic partnership with stakeholders to reduce application processes
	Inadequate monitoring systems to monitor organisational performance	1. Develop and approve performance management policy 2. Develop performance management systems in line with IT Digitization Strategy
	Inadequate Business Performance and Quality Standards	1. Benchmarking of strategies and policies on Governance and Quality Management Systems
<b>Operational Risks</b>		
Governance risks	Non-compliance with legislation, policies, procedures, and standards	1. Recruitment strategy in place to build internal capacity to meet compliance requirements
	Fraud, theft and corruption	1. Implement the Anti-Fraud and Prevention Strategy and conduct training and awareness sessions to build an ethical culture

### **3. PUBLIC ENTITIES**

Not applicable.

### **4. INFRASTRUCTURE PROJECTS**

Not applicable.

### **5. PUBLIC-PRIVATE PARTNERSHIPS**

Not applicable.

## PART D: TECHNICAL INDICATOR DESCRIPTIONS

### 1. PROGRAMME 1: LEADERSHIP AND SUPPORT

1.1 Indicator Title	Unqualified audit opinion obtained on the annual financial statements
<b>Definition</b>	The results of the audits that are undertaken annually by the Auditor-General based on the assessment of performance during the preceding year; which factors both financial performance and performance against predetermined objectives or non-financial performance as prescribed by the Public Finance Management Act
<b>Source of Data</b>	Availability of the external or Auditor-General's audit opinion available in Quarter 2, based on the previous financial year's performance
<b>Method of Calculation or Assessment</b>	Document verification based on the existence and availability of the external or Auditor-General's audit opinion issued during Quarter 2, based on the previous financial year's performance
<b>Means of Verification</b>	Auditor-General's Report
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>Desired performance to turn around the current qualified audit outcome will be supported by risk management issues being effectively institutionalised and introducing rigorous processes necessary to produce a positive audit outcome</li> <li>No legislative or policy changes to the current auditing plans and cycles</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Non-cumulative
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	To first attain and then maintain an unqualified audit outcome annually over the MTSF period, evidenced by the external or Auditor-General's audit opinion available in Quarter 2, based on the previous financial year's performance
<b>Indicator Responsibility</b>	Chief Financial Officer

<b>1.2 Indicator Title</b>	Total revenue generated from fees in the financial year
<b>Definition</b>	The total revenue generated from collection of fees for services rendered
<b>Source of Data</b>	Income statements
<b>Method of Calculation or Assessment</b>	Total revenue recognised based on service rendered
<b>Means of Verification</b>	Finance quarterly reports and Annual Financial Statements
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>• The quantity of services completed outside of the predefined timelines can result in a deviation from target</li> <li>• The assumption of number of applications made with the applicator is supplier dependent and this in turn is dependent on the economy and state of investment</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-end)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	To strive towards optimised fees collection for services rendered by ensuring all monies paid are accounted for by a completed service rendered.
<b>Indicator Responsibility</b>	Chief Financial Officer



<b>1.3 Indicator Title</b>	Break-even of expenses and revenue by 31 March
<b>Definition</b>	A zero balance or surplus at the end of the financial year post reconciling income and expenses
<b>Source of Data</b>	Balance sheets and reconciliation statements
<b>Method of Calculation or Assessment</b>	Total income less total expenditure
<b>Means of Verification</b>	Finance quarterly reports and Annual Financial Statements
<b>Assumptions</b>	Rigorous control over budget spending
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Non-cumulative
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	To achieve a $\geq$ zero or surplus balance at end of financial year in accordance with the Public Finance Management Act
<b>Indicator Responsibility</b>	Chief Financial Officer

<b>1.4 Indicator Title</b>	Percentage of prioritised recommendations from the survey implemented
<b>Definition</b>	Annual survey recommendations defined, addressed and monitored
<b>Source of Data</b>	Web-based enquiries, IT tracking system, Application tracking tool, HR climate survey, Reports from the communications office, HR updates on positions filled and skills audit
<b>Method of Calculation or Assessment</b>	Numerator: Number of prioritised recommendations implemented / Denominator: Number of prioritised recommendations x 100
<b>Means of Verification</b>	Supporting documents to prove that recommendations were implemented
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>• Functional tracking checker</li> <li>• Managers are responding to the complaints sent via the web-based tracking tool</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	All recommendations from the survey implemented
<b>Indicator Responsibility</b>	Manager: Communications

<b>1.5 Indicator Title</b>	Percentage of the change management intervention implemented
<b>Definition</b>	Initiatives conducted towards change management practices
<b>Source of Data</b>	Change management implementation plan
<b>Method of Calculation or Assessment</b>	The number of change management interventions implemented
<b>Means of Verification</b>	Report on the implementation of the change management intervention
<b>Assumptions</b>	Availability of funds to implement the activities
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	Implementation of all the change management interventions
<b>Indicator Responsibility</b>	Executive Manager: Human Resources

1.6 Indicator Title	Percentage of the Workplace Skills Plan implemented
<b>Definition</b>	A tool to assist SAHPRA identify and address their learning and development needs
<b>Source of Data</b>	Workplace Skills Plan
<b>Method of Calculation or Assessment</b>	The number initiatives in the Plan implemented
<b>Means of Verification</b>	Report on the implementation of the Workplace Skills Plan
<b>Assumptions</b>	Availability of funds to implement the Plan
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	Full implementation of the Workplace Skills Plan
<b>Indicator Responsibility</b>	Executive Manager: Human Resources

1.7 Indicator Title	Percentage of positions in the staff establishment filled
<b>Definition</b>	Vacant position identified for relevant recruitment phase and with approved budget are filled before commencement of next phase in the next financial year
<b>Source of Data</b>	Staff establishment, published advertisements, new contracts dated with date of on boarding.
<b>Method of Calculation or Assessment</b>	Numerator: Number of positioned filled / Denominator: Number of positions in the staff establishment x100
<b>Means of Verification</b>	Human resource documents in the Personnel File
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>Executive Manager: HR will be appointed before the beginning of the 2021/22 financial year</li> <li>Recruitment process is supported by organised labour</li> <li>Availability of funds</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Targets for female staff must align with targets set as per the HR Recruitment and Selection Policy
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	SAHPRA establishes a competent workforce through timeous recruitment against the phased plan
<b>Indicator Responsibility</b>	Executive Manager: Human Resources

1.8 Indicator Title	Number of business processes digitalised
<b>Definition</b>	<p>Convert SAHPRA core business processes from manual or semi-automated functioning to fully digital end to end system for application submission, tracking, review and reporting</p> <p>Processes to be mapped: orthodox medicine registration, Section 21 and veterinary medicines</p>
<b>Source of Data</b>	ICT strategic implementation plan
<b>Method of Calculation or Assessment</b>	Number of core business processes digitalised /number of core business processes
<b>Means of Verification</b>	Actual business processes digitalised
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>• Capital</li> <li>• Business process mapping completed</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-end)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	The core programmes will have an end-to-end track and trace system to permit oversight and checkpoint reporting with ability to determine root cause of non-performing sectors
<b>Indicator Responsibility</b>	Senior Manager: Information Technology

## 2. PROGRAMME 2: HEALTH PRODUCTS AUTHORISATION

2.1 Indicator Title	Percentage of medicine registrations in the backlog cleared
<b>Definition</b>	Quantification of backlog applications lodged by pharmaceutical sector that the regulator can process and finalise within a period of 250 working days counting from the day when the applications are deemed to be meeting minimum requirements
<b>Source of Data</b>	Applications that were received by abovementioned applicants through SAHPRA backlog eradication project
<b>Method of Calculation or Assessment</b>	Numerator: Number of Registrations, Rejections and Official Withdrawals / Denominator: Number of New Registration Applications received (actual resubmissions) from Go-Live (1 August 2019) x 100
<b>Means of Verification</b>	Trackers generated from Google Sheets and supporting documentation thereof
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>• The project will continue to receive funding to support accelerated output</li> <li>• The programme will recruit evaluators as per the stated timeline</li> <li>• Ongoing collaboration with Industry stakeholder to submit within the stipulated window</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	To eradicate the backlog of applications by 2022
<b>Indicator Responsibility</b>	Project Manager: Backlog

<b>2.2 Indicator Title</b>	Percentage of medicine variation applications in the backlog cleared
<b>Definition</b>	Quantification of variation applications lodged by pharmaceutical sector that the Backlog Clearance Programme can process and approve or reject
<b>Source of Data</b>	Variation applications that were received from abovementioned applicants through SAHPRA backlog eradication project
<b>Method of Calculation or Assessment</b>	Numerator: Number of Approvals, Rejections and Official Withdrawals / Denominator: Number of Variation Applications received (actual resubmissions) from Go-Live (1 August 2019) x 100
<b>Means of Verification</b>	Trackers generated from Google Sheets and supporting documentation thereof
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>• The project will continue to receive funding to support accelerated output</li> <li>• The programme will recruit evaluators as per the stated timeline</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	To eradicate the backlog of applications by 2022
<b>Indicator Responsibility</b>	Project Manager: Backlog



<b>2.3 Indicator Title</b>	Percentage of New Chemical Entities finalised within 590 working days
<b>Definition</b>	Quantification of new chemical entities finalised within 590 working days, calculated from the day when the applications passes technical screening
<b>Source of Data</b>	SAHPRA Project Management Office generated from Google Sheets
<b>Method of Calculation or Assessment</b>	Numerator: Number of NCE medicines finalised within 590 days / Denominator: Number of NCE applications finalised x 100
<b>Means of Verification</b>	Line listing and supporting documentation thereof
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>• Introduction of the new technology system will not disrupt the operations and the reporting ability</li> <li>• Suitably qualified staff will be successfully recruited</li> <li>• Competing priorities for resources with backlog will be resolved</li> <li>• Internal processes such as reliance arrangements and batch processing are in place and work effectively</li> <li>• Tedious processes currently in terms of new requirements and templates will have been resolved</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	Efficient registration of innovator or novel medication that meets high quality, safety and efficacy standards to enable access to medicines for the benefit of the South African public
<b>Indicator Responsibility</b>	Senior Manager: Health Products Authorisations

<b>2.4 Indicator Title</b>	Percentage of generic medicines finalised within 250 working days
<b>Definition</b>	Quantification of generic medicines finalised within 250 working days, calculated from the day when the applications passes technical screening
<b>Source of Data</b>	SAHPRA Project management Office generated from Google Sheets
<b>Method of Calculation or Assessment</b>	Numerator: Number of generic medicines finalised within 250 working days / Denominator: Number of generic medicine finalised x 100
<b>Means of Verification</b>	Line listing and supporting documentation thereof
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>• Introduction of the new technology system will not disrupt the operations and the reporting ability</li> <li>• Suitably qualified staff will be successfully recruited to meet the demands of increasing number of generic applications</li> <li>• Alignment with processes implemented in terms of new requirements and templates will have been resolved</li> <li>• Competing priorities for resources with backlog will be resolved</li> <li>• Internal processes such as reliance arrangements and batch processing are in place and work effectively</li> <li>• Regulator will continually receive applications for registration of generic medicines as part of its core business</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	Efficient registration of generic medication that meets high quality, safety and efficacy standards to enable access to medicines for the benefit of the South African public
<b>Indicator Responsibility</b>	Senior Manager: Health Products Authorisations

2.5 Indicator Title	Percentage of the Quality Management System requirements implemented
<b>Definition</b>	Assess level of completion and implementation of operational framework against standardised and approved policies, procedures and guidelines for core programmes
<b>Source of Data</b>	Site master file for Regulator
<b>Method of Calculation or Assessment</b>	Numerator: Number of policies and procedures implemented for all identified business processes in core programme/ Denominator: Number of all identified business processes in core programme x 100
<b>Means of Verification</b>	Report on the implementation of Quality Management System requirements implemented
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>• Business process mapping for core programmes is completed</li> <li>• Approval by technical oversight and regulatory strategy committee is regular</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Non-cumulative
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	Full implementation of the Quality Management System requirements
<b>Indicator Responsibility</b>	Chief Operations Officer

<b>2.6 Indicator Title</b>	WHO maturity level obtained
<b>Definition</b>	Successful completion of the WHO benchmarking audit
<b>Source of Data</b>	WHO audit outcome and report
<b>Method of Calculation or Assessment</b>	Maturity level obtained
<b>Means of Verification</b>	Report on the WHO benchmarking audit
<b>Assumptions</b>	Preparedness of SAHPRA for audit in 2021
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Non-cumulative
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	Establish SAHPRA legitimacy as a key health product regulator in African continent and globally
<b>Indicator Responsibility</b>	Chief Operations Officer

### 3. PROGRAMME 3: INSPECTORATE AND REGULATORY COMPLIANCE

3.1 Indicator Title	Percentage of new GMP and GWP related licenses finalised within 125 working days
<b>Definition</b>	Quantification of new GMP and GWP related licence applications lodged by health product sector manufacturers, importer/exporters and wholesalers/distributors, that the regulator can process and finalise within a period of 125 working days counting from the day when the applications are deemed to be meeting minimum requirements for processing
<b>Source of Data</b>	Licensing Unit that receives applications submitted by abovementioned applicants through dedicated email inbox for license applications
<b>Method of Calculation or Assessment</b>	Numerator: Number of applications finalised within 125 working days / Denominator: Number of applications finalised x 100
<b>Means of Verification</b>	<ul style="list-style-type: none"> <li>• Application Email</li> <li>• Acknowledgment Letter</li> <li>• Inspection outcome documentation</li> <li>• Issued Licence</li> <li>• Chief Executive Officer Approval date</li> </ul>
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>• New applications will continue to be received by the regulator</li> <li>• Inspections preceding the processing of applications will be undertaken and completed timeously</li> <li>• Sites will be found to be meeting minimum requirements as per applicable guidelines communicated to industry</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Bi-annually
<b>Desired Performance</b>	To strive to expeditiously process the highest possible number of licence applications to ensure that health products meet quality, safety and efficacy (QSE) standards without compromising the quality of the application process
<b>Indicator Responsibility</b>	Senior Manager: Inspectorate and Regulatory Compliance

3.2 Indicator Title	Percentage of permits finalised within 20 working days
<b>Definition</b>	Quantification of permits lodged by health product sector manufacturers, importer/exporters and wholesalers/distributors, that the regulator can process and finalise within a period of 20 working days counting from the day when the applications are received
<b>Source of Data</b>	Regulatory Compliance Unit that receives applications submitted by abovementioned applicants through dedicated email inbox for permit applications
<b>Method of Calculation or Assessment</b>	Numerator: Number of applications finalised within 20 working days / Denominator: Number of applications finalised x 100
<b>Means of Verification</b>	<ul style="list-style-type: none"> <li>• Application Email</li> <li>• Issued Permit</li> <li>• Chief Executive Officer approval date on approval routing form</li> </ul>
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>• New applications will continue to be received by the regulator</li> <li>• All permits processed are approved</li> <li>• Chief Executive Officer maintains delegation from the Director-General: Health for authorising permits or legislation is amended from Director-General: Health approval to Chief Executive Officer approval in the Medicines Act</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	Permits are finalised within 20 working days
<b>Indicator Responsibility</b>	Senior Manager: Inspectorate and Regulatory Compliance

3.3 Indicator Title	Percentage of health product quality complaint reports produced within 30 working days
<b>Definition</b>	Quantification of investigations conducted in response to health product quality complaints received by the regulator that the regulator can process and finalise within a period of predefined timeline of when complaint is received to when investigations is either closed, actioned or handed over to alternate authority
<b>Source of Data</b>	Signed Investigations reports received
<b>Method of Calculation or Assessment</b>	Numerator: Number of investigation reports finalised within 30 working days / Denominator: Number of complaints received x 100
<b>Means of Verification</b>	<ul style="list-style-type: none"> <li>• Complaint trigger evidence or documented receipt details from inspector</li> <li>• Completed investigation report</li> <li>• Investigation Report tracker</li> </ul>
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>• That new recruits will be successfully on boarded to fill current critical vacancies</li> <li>• Internal business processes are in place and optimized with policies and procedures to support operations</li> <li>• Digitisation solution in place</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	To endeavour to conduct the highest possible number of post marketing investigations to keep the public and consumers protected from effects of negative post marketing behaviour, poor product quality and product safety concerns
<b>Indicator Responsibility</b>	Senior Manager: Inspectorate and Regulatory Compliance

## 4. PROGRAMME 4: CLINICAL AND PHARMACEUTICAL EVALUATION

<b>4.1 Indicator Title</b>	Percentage applications for the sale of unregistered Category A (human) medicines finalised within 24 working hours
<b>Definition</b>	Timebound indicator reflecting the response to public health needs for unregistered Category A medicines. Unregistered medicines are medicines that do not appear on the SAHPRA medicine register whereas Category A medicines are referred to as orthodox or allopathic medicines
<b>Source of Data</b>	SAHPRA's Section 21 Unit, generated through Google sheets
<b>Method of Calculation or Assessment</b>	Numerator: Number of applications finalised within 24 working hours / Denominator: Number of applications received x 100
<b>Means of Verification</b>	<ul style="list-style-type: none"> <li>• S21 applications captured on Google Sheets</li> <li>• Emailed Proof of Payment</li> <li>• Letter of S21 Authorization</li> </ul>
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>• System is running continually without disruptions</li> <li>• Applicants observe application rules and procedures as communicated to them</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	Facilitate the most efficient possible access to unregistered Category A medicines that fulfil a public health mandate of the regulator
<b>Indicator Responsibility</b>	Senior Manager: Clinical Evaluation and Management



4.2 Indicator Title	Percentage of human clinical trial applications finalised within 90 working days
<b>Definition</b>	Quantification of clinical trial applications lodged with the regulator by applicants who intend to undertake clinical trials for purposes of assessing GCP and ethical compliance for human participation in clinical trials
<b>Source of Data</b>	Clinical Trials business unit generated from dated clinical trial reports signed off by the clinical trials unit manager with supplementary evidence of Minutes signed off by the clinical trial committee chairperson
<b>Method of Calculation or Assessment</b>	Numerator: Number of clinical trial applications finalised within 90 working days / Denominator: Number of clinical trial applications finalised x 100
<b>Means of Verification</b>	<ul style="list-style-type: none"> <li>• Emailed CTF1</li> <li>• Emailed Proof of Payment</li> <li>• CTC meeting minutes</li> <li>• Approval/Rejection letter</li> </ul>
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>• Clinical trials not completed within a cycle will be included in the following cycle</li> <li>• SOPs guiding the work of the external evaluators will be concluded timeously</li> <li>• Necessary delegations will be finalised for sign-off purposes</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	Facilitation of efficient processing of clinical trial applications to enable access to research and development within an environment that guarantees the safety of clinical trial participants
<b>Indicator Responsibility</b>	Senior Manager: Clinical Evaluation and Management

4.3 Indicator Title	Percentage of reports on health product safety signals issued within 40 working days
<b>Definition</b>	<p>Quantification of medicine safety communication alerts relating to new adverse events and signals that have been subjected to necessary assessments after their receipt by the regulator and the decision is reached to publish them to alert the public. Such alerts are handled in the following forms:</p> <ul style="list-style-type: none"> <li>• Media releases: local safety concerns that warrant immediate public awareness, published safety decisions by other regulatory authorities, safety signals.</li> <li>• Dear healthcare professional letters: safety concern for immediate attention of healthcare professionals from safety notifications, internal reviews</li> <li>• Medicines safety alerts: educational or informational material for healthcare professionals on health products safety issues from internal reviews</li> <li>• Safety surveillance: notifications from applicants, internet, and media searches; and</li> <li>• Safety signal: Adverse drug reaction reports from Healthcare professionals, consumers and applicants, literature, VigiBase®</li> </ul>
<b>Source of Data</b>	Media Releases generated; DHCPLs generated; Medicines Safety Alerts generated
<b>Method of Calculation or Assessment</b>	Numerator: Number of safety concerns issued within 40 working days / Denominator: Number of safety concerns received x 100
<b>Means of Verification</b>	<ul style="list-style-type: none"> <li>• Media Releases generated</li> <li>• DHCPLs generated</li> <li>• Medicines Safety Alerts generated</li> </ul>
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>• Applicants will notify the Authority of foreign Regulatory Authority decisions which concerns their health products</li> <li>• Applicants will comply with Authority's recommendations</li> <li>• Necessary resources such as reliable Internet connectivity, reference material, adequate, competent human resources and ICT support are in place</li> <li>• Active surveillance of medicine safety issues will remain in force.</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	Timeous communication of regulatory decisions on the safety of health product, to promote public health of South Africans
<b>Indicator Responsibility</b>	Senior Manager: Clinical Evaluation and Management

<b>4.4 Indicator Title</b>	Number of safety awareness webinars held
<b>Definition</b>	A workshop to educate the public and other stakeholders on the importance of health product safety reporting
<b>Source of Data</b>	Webinar agenda and video
<b>Method of Calculation or Assessment</b>	Simple count on the number of webinars held
<b>Means of Verification</b>	Webinar agenda and video
<b>Assumptions</b>	<ul style="list-style-type: none"> <li>• Regulator will continually receive ADR reports from applicants, healthcare professionals and consumers</li> <li>• Necessary resources such as reliable Internet connectivity, reference material, adequate, competent human resources and ICT support are in place</li> </ul>
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-end)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	Increase in vigilance reports
<b>Indicator Responsibility</b>	Senior Manager: Clinical Evaluation and Management

## 5. PROGRAMME 5: MEDICAL DEVICES AND RADIATION CONTROL

5.1 Indicator Title	Percentage of medical device establishment licence applications finalised within 90 days
<b>Definition</b>	Quantification of the percentage of new medical device establishment applications for licences lodged with the regulator as prescribed by the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), as amended
<b>Source of Data</b>	Medical device applications and licences issued herewith
<b>Method of Calculation or Assessment</b>	Numerator: Number of new licences applications finalised within 90 working days / Denominator: Number of applications finalised
<b>Means of Verification</b>	The finalised licence and the proof of payments for licence applications and licences
<b>Assumptions</b>	All tools necessary for processing applications are available and function optimally
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	Maintaining the highest possible levels of quality and safety for medical device establishments manufacturing or importing and exporting of medical devices to ensure the public and the environment
<b>Indicator Responsibility</b>	Senior Manager: Medical Devices and Radiation Control

<b>5.2 Indicator Title</b>	Medical device registration regulations implemented
<b>Definition</b>	Quantification of the extent of progress made in developing and implementing the medical device framework for registration of medical devices
<b>Source of Data</b>	Revised medical device roadmap, TORS minutes , Progress report to the Chief Regulatory Officer and Chief Executive Officer
<b>Method of Calculation or Assessment</b>	Count steps in framework completed
<b>Means of Verification</b>	<ul style="list-style-type: none"> <li>• Published Regulations and Guidelines</li> <li>• Finalised and Signed framework</li> </ul>
<b>Assumptions</b>	Human resource capacity to champion project
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Non-cumulative
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	Framework to register medical devices implemented
<b>Indicator Responsibility</b>	Senior Manager: Medical Devices and Radiation Control

<b>5.3 Indicator Title</b>	Percentage of applications for radionuclide authorities finalised within 30 working days
<b>Definition</b>	Quantification of the percentage finalised of new applications for licences lodged with the regulator by holders of radionuclides as prescribed by the Hazardous Substances Act, 1973, as amended
<b>Source of Data</b>	Line listing extracted from radionuclide Oracle database
<b>Method of Calculation or Assessment</b>	Numerator: Number of new licences finalised within 30 working days / Denominator: Number of applications finalised x 100
<b>Means of Verification</b>	Excel calculation performed on line listing and supporting documentation thereof
<b>Assumptions</b>	That all resources necessary for processing applications and measuring performance are available and function optimally
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	Maintaining the highest possible levels of protection of radiation workers, patients, public and the environment against the adverse effects of radiation. efficient processing. Maintaining most effective possible processing of license applications.
<b>Indicator Responsibility</b>	Senior Manager: Medical Devices and Radiation Control

<b>5.4 Indicator Title</b>	Percentage of licence applications for listed-electronic products finalised within 30 working days
<b>Definition</b>	Quantification of the percentage finalised of new applications for licences to import listed electronic products lodged with the regulator as prescribed by the Hazardous Substances Act, 1973 (Act No. 15 of 1973), as amended
<b>Source of Data</b>	Import licence applications, licences and not-licensable letters
<b>Method of Calculation or Assessment</b>	Numerator: Number of new applications finalised within 30 working days / Denominator: Number of applications finalised x 100
<b>Means of Verification</b>	Line listing and supporting documentation thereof
<b>Assumptions</b>	All resources necessary for processing applications and measuring performance are available and function optimally
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Cumulative (year-to-date)
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	Maintaining the required levels of safety, quality and performance of imported listed electronic products to ensure health and safety of patients, healthcare workers, industry and the public
<b>Indicator Responsibility</b>	Senior Manager: Medical Devices and Radiation Control

5.5 Indicator Title	Approved Co-Regulation Model
<b>Definition</b>	A framework on how SAHPRA and the National Nuclear Regulator will work together on radiation control matters
<b>Source of Data</b>	SAHPRA/NNR Working Group
<b>Method of Calculation or Assessment</b>	Approved Co-Regulation Model
<b>Means of Verification</b>	Co-Regulation Model that is approved by the Board
<b>Assumptions</b>	Cooperation between the two regulators
<b>Disaggregation of Beneficiaries (where applicable)</b>	Not applicable
<b>Spatial Transformation (where applicable)</b>	Not applicable
<b>Calculation Type</b>	Non-cumulative
<b>Reporting Cycle</b>	Quarterly
<b>Desired Performance</b>	Approved Co-Regulation Model with the National Nuclear Regulator
<b>Indicator Responsibility</b>	Legal Regulatory Advisor



## ANNEXURES

### ANNEXURE A: MATERIALITY AND SIGNIFICANCE FRAMEWORK

#### Background

In terms of the Treasury Regulation Section 28.3.1 – “For purposes of material [sections 55(2) of the Public Finance Management Act (PFMA)] and significant [section 54(2) of the PFMA], the accounting authority must develop and agree on a framework of acceptable levels of materiality and significance with the relevant executive authority.

The South African Auditing Standard (SAAS 320.03) defines materiality as follows: “Information is material if its omission or misstatement could influence the economic decisions of users taken on the basis of the financial statements. Materiality depends on the size of the item or error judged in the particular circumstances of its omission or misstatement. Thus, materiality provides a threshold or cut-off point, rather than being a primary qualitative characteristic, which information must have if it is to be useful.”

Accordingly, we will be dealing with this framework under two main categories, being quantitative and qualitative aspects.

Materiality can be based on a number of financial indicators. Detailed below is an indicative table of financial indicators as documented in the Treasury Practice note on applications under S.54 of the PFMA.

Basis	Acceptable Percentage Range
Total assets	1 % - 2 %
Total Revenue	0,5 % - 1 %
Profit after tax	2 % - 5 %

SAHPRA will use 1 % of total revenue to determine materiality. SAHPRA operations are driven mainly by applications received and are therefore essentially revenue-driven. In determining the materiality value as 1 % we have considered the following factors:

#### a) Nature of the SAHPRA’s business

In terms of the Medicines Act, the objects of the Authority are to provide for the monitoring, evaluation, regulation, investigation, inspection, registration and control of medicines, scheduled

substances, clinical trials and medical devices, radiation control and related matters in the public interest.

**b) The control and inherent risks associated with the SAHPRA**

In assessing the control risk of the SAHPRA, and concluding that a materiality level higher than 0,25 % can be used due to a good control environment being present cognizance was given to amongst others:

- Proper and appropriate governance structures have been established;
- An audit and risk committee that closely monitors the control environment of the SAHPRA was established;
- The function of internal audit was partly outsourced to a firm with SAHPRA specific experience; and
- A three-year internal audit plan, based on annual risk assessments being performed, is annually reviewed and agreed by the audit committee.

**c) Quantitative Aspects**

**Materiality Level**

The level of materiality for 2021/22 has been set as follows: 0.5% of revenue.

**d) Qualitative Aspects**

Materiality is not merely related to the size of the entity and the elements of its financial statements. Obviously, misstatements that are large either individually or in the aggregate may affect a “reasonable” user’s judgement. However, misstatements may also be material on qualitative grounds. These qualitative grounds include amongst others:

- i) New ventures that the SAHPRA has entered into.
- ii) Unusual transactions entered into that are not of a repetitive nature and are disclosable purely due to the nature thereof due to knowledge thereof affecting the decision making of the user of the financial statements.
- iii) Transactions entered into that could result in reputational risk to SAHPRA.
- iv) Any fraudulent or dishonest behaviour of an officer or staff of SAHPRA.
- v) Procedures/processes required by legislation or regulation (e.g. PFMA and the Treasury Regulations)

## Statutory Application

### ***Section 50: Fiduciary duties of accounting authorities:***

- 1) The accounting authority for a public entity must –

PFMA Section	Quantitative [Amount]	Qualitative [Nature]
(c) on request, disclose to the executive authority responsible for that public entity or the legislature to which the public entity is accountable, all material facts, including those reasonably discoverable, which in any way may influence the decisions or action of the executive authority or that legislature	Disclose all material facts	The Board will disclose to the National Department of Health all material facts as requested and all material facts not requested, including those reasonably discoverable, which in any way may influence the decisions or action of the National Department of Health, at the discretion of the Board

### ***Section 51: General responsibilities of accounting authorities:***

- 1) An accounting authority for a public entity –

PFMA Section	Quantitative [Amount]	Qualitative [Nature]
(g) must promptly inform the National Treasury on any new entity which that public entity intends to establish or in the establishment of which it takes the initiative, and allow the National Treasury a reasonable time to submit its decision prior to formal establishment; and	Disclose all material facts timeously	Full particulars to be disclosed to the Minister of Health for approval after which it is to be presented to Treasury

### ***Section 54: Information to be submitted by accounting authorities:***

- 2) Before a Public Entity concludes any of the following transactions, the Accounting Authority for the Public Entity must promptly and in writing inform the relevant Treasury of the transaction and submit relevant particulars of the transaction to its Executive Authority for approval of the transaction:

PFMA Section	Quantitative [Amount]	Qualitative [Nature]
a) establishment of a company;	Any proposed establishment of a legal entity	Full particulars to be disclosed to the Minister of Health and Minister of Finance (National Treasury) for approval (simultaneous submission)
b) participation in a significant partnership, trust, unincorporated joint venture or similar arrangement;	Qualifying transactions exceeds (based on 0.5 % of total SAHPRA Revenue, as at 31 March). This includes collaborative arrangements	
c) acquisition or disposal of a significant shareholding in a company;	Greater than 20 % of shareholding	
d) acquisition or disposal of a significant asset;	Qualifying transactions exceeds (based on 0.5 % of total SAHPRA Revenue, as at 31 March). Including Financial Leases	Any asset that would increase or decrease the overall operational functions of the Authority, outside of the approved strategic plan and budget
e) commencement or cessation of a significant business activity; and	Any activity not covered by the mandate / core business of the Authority and that exceeds the Qualifying transactions exceeds (based on 0.5 % of total SAHPRA Revenue, as at 31 March)	Full particulars to be disclosed to the Minister of Health and Minister of Finance (National Treasury) for approval (simultaneous submission)
f) a significant change in the nature or extent of its interest in a significant partnership, trust, unincorporated joint venture or similar arrangement	Qualifying transactions exceeds (based on 0.5 % of total SAHPRA Revenue, as at 31 March)	

### ***Section 55: Annual report and financial statements***

- 2) The annual report and financial statements referred to in subsection (1) (d) ("financial statements") must -
  - a) fairly present the state of affairs of the Public Entity, its business, its financial results, its performance against predetermined objectives and its financial position as at the end of the financial year concerned;
  - b) include particulars of -

PFMA Section	Quantitative [Amount]	Qualitative [Nature]
(i) any material losses through criminal conduct and any irregular expenditure and fruitless and wasteful expenditure that occurred during the financial year;	All instances	<ul style="list-style-type: none"> <li>Report quarterly to the Minister of Health</li> <li>Report annually in the Annual Financial Statements</li> </ul>
(ii) any criminal or disciplinary steps taken as a consequence of such losses or irregular expenditure or fruitless and wasteful expenditure;		
(iii) any losses recovered or written off;		
(iv) any financial assistance received from the state and commitments made by the state on its behalf; and		
(v) any other matters that may be prescribed	All instances, as prescribed	

### ***Section 56: Assignment of powers and duties by accounting authorities***

PFMA Section	Quantitative [Amount]	Qualitative [Nature]
1) The accounting authority for a public entity may— (a) In writing delegate any of the powers entrusted or delegated to the accounting authority in terms of this Act, to an official in that public entity; (b) Instruct an official in that public entity to perform any of the duties assigned to the accounting authority in terms of this Act	Values excluded from the Delegation of Authority Framework Policy	Instances that are excluded from the Delegation of Authority Framework Policy
2) A delegation or instruction to an official in terms of subsection (1)— (c) Is subject to any limitations and conditions the accounting authority may impose; (d) May either be to a specific individual or to the holder of a specific post in the relevant public entity; and (e) Does not divest the accounting authority of the responsibility concerning the exercise of the delegated power or the performance of the assigned duty	Values excluded from the Delegation of Authority Framework Policy	Instances that are excluded from the Delegation of Authority Framework Policy





**health**

Department:  
Health  
REPUBLIC OF SOUTH AFRICA

Reference No:

Enquiries: Dr T Pillay

Office No: S0817

Extension: 8170

Date: 05 MARCH 2021

THE MINISTER

**SUBJECT: APPROVAL OF THE SAHPRA'S REVISED STRATEGIC PLAN (2020/21-2024/25) AND ANNUAL PERFORMANCE PLAN, PROPOSED BUDGET AND THE MATERIALITY AND SIGNIFICANCE FRAMEWORK OF THE SOUTH AFRICAN HEALTH PRODUCTS REGULATORY AUTHORITY 2021/22 FINANCIAL YEAR**

#### PURPOSE

1. To request the Minister to consider, approve and sign, should the Minister agree with the contents therein:
  - (a) the South African Health Products Regulatory Authority's (SAHPRA) revised Strategic Plan (SP) for 2020/21-2024/25 (**Annexure A**);
  - (b) the SAHPRA's Annual Performance Plan (APP); proposed budget and the Materiality and Significance Framework for the 2021/22 financial year (**Annexure B**); and
  - (c) the letter addressed to the Chairperson of the SAHPRA, Prof. Helen Rees, communicating such approval (**Annexure C**).

#### SUMMARY

2. The SAHPRA submitted to the Department for consideration and approval by the Minister the Revised Strategic Plan (SP) 2020/21-2024/25 (**Annexure A**) and Annual Performance Plan and the Materiality and Significance Framework for the 2021/22 (**Annexure B**) financial year in accordance with the Treasury Regulations made in Public Finance Management Act, 1999 (Act No. 1 of 1999) ("the PFMA").
3. Submission of the above-mentioned document is further made in terms of the *Revised Framework for Strategic Plans and Annual Performance Plans* ("the Framework"), issued by the National Treasury to guide the development of Strategic Plans and Annual Performance Plans in the public service.
4. In accordance with the *Revised Framework for Strategic Plans and Annual Performance Plans* (the Framework) issued by the National Treasury, Strategic Plans are to cover a five (5) year period, and should be approved once every five (5) years by the Executive Authority. However, the SAHPRA is submitting a revised SP.



## STRATEGIC FOCUS OF THE SUBMISSION (APP AND STRATEGIC PLAN)

5. The SAHPRA was established in terms of the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965) as amended, for the purpose of monitoring, evaluation, regulation, investigation, inspection, registration and control of medicines, Scheduled substances, clinical trials and medical devices, IVDs and related matters in the public interest.

## DISCUSSION

6. The *Revised Framework for Strategic Plans and Annual Performance Plans* provides the principles for short and medium term planning for government institutions, outlines the alignment of various institutional plans to high-level government long and medium term plans, as well as institutional processes for the different types of plans.
7. SAHPRA is responsible for the:
  - (a) Regulation of health products intended for human and animal use;
  - (b) Licencing of manufacturers, wholesale and distributors of medicines, medical devices, radiation emitting devices and radioactive nuclides; and
  - (c) Conduct of clinical trials.
8. The Revised SP (2020/21-2024/25) of the SAHPRA reflects the following seven (7) strategic outcomes:
  - (a) Effective financial management;
  - (b) Financial sustainability achieved through revenue generated and enhanced operational efficiencies;
  - (c) Continuously respond to the needs and expectations of SAHPRA stakeholders;
  - (d) A positive and enabling working culture created;
  - (e) Attract and retain superior talent;
  - (f) Strengthened Information and Communication Technology and digitisation; and
  - (g) High levels of organisational operational efficiency and effectiveness in the regulatory function maintained.
9. During the 2019/20 financial year, the Board approved the review of SAHPRA fees. The fees had not been reviewed since 2017. Recommendations were made to the Minister of Health and the revised fees were published for comment in June 2020. The comments were considered by SAHPRA and further recommendations were made to the Minister of Health. These fees would be implemented in the later part of the 2020/21 financial year.
10. There is currently a significant opportunity to boost earnings revenue from the provision of a range of services such as registering medical devices and licensing of electronic generators of radiation and radionuclides.
11. SAHPRA is estimating that revenue generated from fees will grow from R162,264 million in 2021/22 to R168,755 million in 2022/23. This is as a result of an increased revenue generating potential which will depend on the range of services that can be charged for, the frequency of the service charges, the volume of services provided and the unit cost of each service.



12. The APP of SAHPRA for the 2021/22 also include the proposed budget for the same period. This is based on Section 53 (1) of the PFMA, where it is stated that the budget of the public entity for any financial year must be approved by the Minister. The Department will make a transfer of R146,287 million to the SAHPRA as allocated.
13. The SAHPRA's materiality and significant value will be 0.5% of the 2019/20 audited revenue as a result the Minister will be required to approve any qualifying transaction above the approved materiality level.
14. Should the Minister endorse the SAHPRA's Revised SP (2020/21-2024/25) and APP (2021/22) financial year, the Minister is kindly requested to consider, approve and sign the letter attached as **Annexure C**, addressed to the Chairperson of the SAHPRA communicating such approval, as well as sign the actual revised SP in particular in **pages iii and ix**, and APP sign **pages iii and ix**.

#### RELEVANCE TO THE NATIONAL DEVELOPMENT PLAN

15. The SAHPRA contributes towards the achievement of the National Development Plan (NDP) goals relating to improving the health and well-being of the South African population through improving quality of care.

#### ORGANISATIONAL AND PERSONNEL IMPLICATIONS

16. Not Applicable.

#### LEGAL IMPLICATIONS

17. Not applicable.

#### COMMUNICATION IMPLICATIONS

18. Not applicable.

MS VM RENNIE  
HEAD: CORPORATE SERVICE  
DATE:

#### FINANCIAL IMPLICATIONS

19. Not applicable.




MR I VAN DER MERWE  
CHIEF FINANCIAL OFFICER  
DATE:



## RECOMMENDATIONS

20. It is recommended that the Minister:

- (a) Approve and sign the SAHPRA's Revised Strategic Plan (2020/21-2024/25) (pages iii and ix), Annual Performance Plan (pages iii and ix), proposed budget and the Materiality and Significance Framework of the South African Health Products Regulatory Authority for the 2021/22 financial year should the Minister's agree with the contents therein (**Annexure A and Annexure B**); and
- (b) sign the letter addressed to the Chairperson of the SAHPRA, Prof. Helen Rees, communicating such approval, should the Minister agree with the contents of the letter (**Annexure C**).

<p>Dr T Pillay: DDG: Health Regulations &amp; Compliance</p>  <p>Date: 08/03/2021 Recommended/ Not recommended</p>	<p>Director-General: Dr SSS Buthelezi</p>  <p>Date: 08/03/2021 Recommended/Not recommended</p>
<p>Dr MJ Phaahla, MP Deputy Minister of Health</p> <p>Date: Supported/ Not supported/ Amended</p>	<p>Dr ZL Mkhize, MP Minister of Health</p>  <p>Date: 08/03/2021 Approved/Not-approved/amended</p>





MINISTRY  
HEALTH  
REPUBLIC OF SOUTH AFRICA

PRETORIA

Private Bag X399, PRETORIA, 0001, 28th Floor, Civitas Building, Cnr Thabo Sehume and Struben Street, PRETORIA, 0001 Tel: (012) 395 8086 Fax: (012) 395 9165

CAPE TOWN

Private Bag X9070, CAPE TOWN, 8000, Room 413, 120 Plain Street, CAPE TOWN, 8000 Tel: (021) 465 7407/8 Fax: (021) 465 1575

Prof. Helen Rees  
Chairperson: South African Health Products Regulatory Authority  
Private Bag x828  
**PRETORIA**  
0001

Dear Prof. Rees

**APPROVAL OF THE SOUTH AFRICAN HEALTH PRODUCTS REGULATORY AUTHORITY'S  
REVISED STRATEGIC PLAN (2020/21-2024/25) AND ANNUAL PERFORMANCE PLAN,  
BUDGET AND THE MATERIALITY AND SIGNIFICANCE FRAMEWORK FOR THE 2021/22  
FINANCIAL YEAR**

The above matter refers.

I hereby approve for implementation, the South African Health Products Regulatory Authority's (OHSC) Revised Strategic Plan (SP) (2020/21-2024/25) and Annual Performance Plan (APP), budget and the materiality/significance framework for the 2021/22 financial year. The materiality and significance value approved in this regard is at R1.3 million.

The above approval is made in terms of Regulation 30.1 of the 2005 *Treasury Regulations for departments, trading entities, constitutional institutions and public entities* issued in terms of the Public Finance Management Act, 1999 (Act No. 1 of 1999) ("the PFMA").

I wish the SAHPRA success in implementing the revised SP and APP for the periods indicated, thus contributing towards achieving the Department of Health's Vision.

I trust that the above is in order.

Yours faithfully

**DR ZL MKHIZE, MP**  
**MINISTER OF HEALTH**

**DATE:** 08/03/2021